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ABSTRACT 
Extracellular Vesicles (EVs), particularly exosomes, are of considerable interest as tumor 
biomarkers, since tumor-derived EVs contain a broad array of information about tumor 
pathophysiology including its metabolic and metastatic status. However, current EV based 
assays cannot distinguish between EV biomarker changes by altered secretion of EVs 
during diseased conditions like cancer, inflammation, etc. that express a constant level of 
a given biomarker,  stable secretion of EVs with altered biomarker expression, or a 
combination of these two factors . This issue was addressed by developing a nanoparticle 
and dye-based fluorescent immunoassay that can distinguish among these possibilities by 
normalizing EV biomarker level(s) to EV abundance, revealing average expression levels 
of EV biomarker under observation. In this approach, EVs are captured from complex 
samples (e.g. serum), stained with a lipophilic dye and hybridized with antibody-
conjugated quantum dot probes for specific EV surface biomarkers. EV dye signal is used 
to quantify EV abundance and normalize EV surface biomarker expression levels. EVs 
from malignant (PANC-1) and nonmalignant pancreatic cell lines (HPNE) exhibited 
similar staining, and probe-to-dye ratios did not change with EV abundance, allowing 
direct analysis of normalized EV biomarker expression without a separate EV 
quantification step. This EV biomarker normalization approach markedly improved the 
ability of serum levels of two pancreatic cancer biomarkers, EV EpCAM and EV EphA2, 
to discriminate pancreatic cancer patients from nonmalignant control subjects. The 
streamlined workflow and robust results of this assay are suitable for rapid translation to 
clinical applications and its flexible design permits it to be rapidly adapted to quantitate 
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other EV biomarkers by the simple swapping of the antibody-conjugated quantum dot 
probes for those that recognize a different disease-specific EV biomarker utilizing a 
workflow that is suitable for rapid clinical translation. 
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PREFACE 
This dissertation includes original research and review articles previously published by the 
primary author. Chapter 1 focuses on the background and role of EVs in infectious disease 
and cancer and Chapter 7 which discusses the future work of the quantum dot assay in 
detection of bacteria related EVs  (Rodrigues, M., J. Fan, C. Lyon, M. H. Wan, and Y. Hu 
(2018). "Role of Extracellular Vesicles in Viral and Bacterial Infections: Pathogenesis, 
Diagnostics, and Therapeutics." Theranostics 8(10): 2709-2721, Copyright 
©2019 Ivyspring International Publisher). Chapter 2 discusses the release of EV in cancer 
vs normal cells, Chapter 3 focuses on the use of a lipid dye to measure the number of EVs 
in a sample, Chapter 4 emphasizes on the use of the two pancreatic cancer-specific markers 
to distinguish between cancer and normal EVs, Chapter 5 discusses about the design and 
development of the quantum dot assay with Chapter 7 covering the clinical validation of 
the assay (Reprinted with permission from Rodrigues, Meryl; Richards, Nicole; Ning, Bo; 
Lyon, Christopher; Hu, Tony, “Rapid lipid-based approach for normalization of quantum 
dot-detected biomarker expression on extracellular vesicles in complex biological 
samples”, Nano Letters Article ASAP, DOI:10.1021/acs.nanolett.9b02232, Copyright © 
2019, American Chemical Society) 
  
 
 
 
                                                                                                                      
 
1 
CHAPTER  
1 BACKGROUND AND RESEARCH OBJECTIVES 
1.1. Introduction 
 Extracellular vesicles (EVs), particularly exosomes, have gained attention for their 
potential as disease biomarkers and therapeutic agents. EVs are exosomes released by the 
endocytic pathway that range from 30-100 nm in diameter, and contain host (and 
pathogen)-derived nucleic acid, protein and lipid cargos. Microvesicles (also known as 
shedding vesicles, ectosomes or microparticles), are a distinct type of exosome that forms 
by the outward budding of the plasma membrane and are 100-1000 nm in diameter. These 
EV types are distinct in their subcellular site of origin and physical parameters, but the size 
overlap of exosomes and microvesicles and differences in exosome isolation and handling 
procedures can lead to confusion, despite ongoing efforts by the International Society for 
Extracellular Vesicles (ISEV) to standardize and harmonize these methods (Witwer, Buzas 
et al. 2013, Lener, Gimona et al. 2015).  
1.1.1. Exosome biogenesis 
Exosomes are formed is a multistep process which includes four stages: initiation, 
endocytosis, multivesicular bodies formation (MVBs) and exosome secretion (Zhang, 
Yuan et al. 2015). It begins with inward invagination of the cellular plasma membrane to 
form an early endosome. The early endosome undergoes several changes as it matures to 
form a late endosome. The limiting membrane of the late endosome undergoes a series of 
inward invaginations resulting in accumulation of intraluminal vesicles (ILVs) and 
formation of MVBs that eventually fuse with the plasma membrane to release exosomes 
into the extracellular space. Recent research in the field has brought to light that exosomes 
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may represent a vehicle for intercellular communication. In fact, exosomes may deliver 
proteins, soluble factors, nucleic acids and RNAs (mRNA and miRNA) and modulate 
protein expression in recipient cells (Rodrigues, Fan et al. 2018). This appears to be of 
great importance for maintaining normal homeostasis of the body and the pathogenesis of 
the disease, including tumors. Studies revealed that Rab guanosine triphosphates (GTPase) 
play a critical role in the regulation of exosome secretion. Studies show that Rab27a/b 
affects the size and localization of MVBs, while Rab3 regulates MVB docking and 
tethering at the plasma membrane (Zhang, Yuan et al. 2015). Apart from Rab GTPase 
playing a role in exosome secretion, there is evidence that accumulation of intracellular 
Ca2+ results in an increase in exosome secretion (Savina, Furlan et al. 2003). Soluble factors 
(e.g., nucleic acids, proteins, carbohydrates, and other factors), are captured from the 
cytosol during endosomal membrane invagination, but these components can be 
preferentially enriched by interaction with endosomal membrane factors, including the 
endosomal sorting complexes required for transport (ESCRTs) which recognize 
ubiquitinylated proteins. Despite much progress in the field, there are significant gaps in 
the understanding of the mechanisms responsible for sorting proteins into internal vesicles 
of multivesicular compartments and, hence, to exosomes (Whiteside 2016, Rodrigues, Fan 
et al. 2018) (Figure 1A).   
1.1.2. Exosomal Cargo 
EVs carry an imprint of their parent cell, which includes nucleic acids, proteins, 
enzymes, lipids, cytokines and other soluble factors but do not completely resemble the 
parent cell (van der Pol, Boing et al. 2012, Raposo and Stoorvogel 2013). Due to their 
endosomal origin, EVs carry components of the endosomal-sorting complex required for 
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transport (ESCRT) along with other ESCRT-associated molecules (Colombo, Moita et al. 
2013). EV membranes are enriched for several broadly expressed tetraspanins proteins , 
including CD9, CD63,  and CD81 - molecules used as EV markers confirming the 
endocytic origin of the vesicles (Andreu and Yanez-Mo 2015). EVs express molecules 
involved in MVB biogenesis such as TSG101 and ALIX, proteins that participate in signal 
transduction such as protein kinase, metabolic enzymes, heat shock proteins (HSP70, HSP 
90), and lipid raft proteins like flotillin-1. They contain membrane trafficking proteins like 
Annexin and Rab family proteins, cytoskeleton proteins like actin and tubulin, and various 
transmembrane proteins (De Toro, Herschlik et al. 2015, Whiteside 2016) (Figure 1B).  
Furthermore, EV-specific protein molecules may be subjected to the cell type or 
tissue birthplace from which the EV originates and may differ based on any physiological 
changes or stimulations the cell underwent. An example of this is the presence of major 
histocompatibility class (MHC) I and II complexes on EVs derived from antigen-
presenting cells such as B-cells or dendritic cells (DCs), or presence of tumor antigens in 
tumor-derived EVs (Rodrigues, Fan et al. 2018). Because of their endosomal origin, 
nuclear, or mitochondrial proteins have not been found in EVs (De Toro, Herschlik et al. 
2015). Further studies have revealed the presence of messenger RNA (mRNA) and 
microRNA (miRNA) in EVs, in addition to other RNA species like transfer RNA, long 
non-coding RNA and even viral RNA.  
1.1.3. EV trafficking and uptake 
Secreted EVs are detectable in most body fluids, including plasma, urine, saliva, 
broncheoalveolar and cerebrospinal fluids, and can interact with cells close to their site of 
origin or at distant anatomical sites after transport through the circulation. Interactions 
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between membrane factors on circulating and target cells appear to control EV uptake 
selectivity. Such uptake primarily occurs phagocytosis, which requires dynamin 2 and 
phosphatidyl inositol-3-kinase, and relies heavily upon surface molecules specific to 
certain cell types (e.g. T-cell membrane protein 4) as well as EV surface proteins, including 
integrins, annexins, galectin, and intercellular adhesion molecule 1 (Pant, Hilton et al. 
2012). However, EV uptake by these recipient cells can alter their gene expression levels 
to alter future EV uptake through the transfer of regulatory mRNAs, miRNAs and 
lncRNAs, cytoplasmic proteins and cell-specific receptors (Matsuo, Chevallier et al. 2004).  
The presence of different types of RNA in EVs can affect the transcriptome of recipient 
cells (Ratajczak, Miekus et al. 2006, Valadi, Ekstrom et al. 2007). EV-derived factors can 
thus alter gene transcription and translation, and regulate signaling cascades to alter 
transcript and protein modifications, protein localization, key enzymatic reactions to 
impact overall cellular homeostasis, with interactions among factors supplied by the EV 
donor and recipient cell determining which molecular mechanisms will predominate (Pant, 
Hilton et al. 2012). The presence of different types of RNA in EVs can affect the 
transcriptome of recipient cells (Ratajczak, Miekus et al. 2006, Valadi, Ekstrom et al. 
2007). 
                                                                                                                      
 
5 
 
Figure 1. (A) Exosome biogenesis begins with the invagination of the plasma membrane 
to generate early endosomes. These endosomes can then invaginate to form intraluminal 
vesicles (ILVs). This process creates multi-vesicular bodies (MVBs) that can then fuse 
with the plasma membrane to release mature ILVs, now called EVs, into the extracellular 
space. (B) Exosomes contain proteins, nucleic acids (including mRNAs, miRNAs, and 
DNA fragments), and lipids, and these cargos can reflect selective incorporation during 
exosome formation in a process controlled by lipid raft proteins, ESCRT accessory proteins 
(e.g., ALIX and TSG101) and tetraspanin proteins. The cytosolic release of these contents 
upon EV uptake can alter the phenotype of the recipient cells. 
 
1.2. Role of EVs in viral and bacterial infections 
 Most cells secrete EVs, but EVs produced during pathogen infections can reveal 
differences in their composition to reflect their origin from infected cells and the overall 
state of the infection. Studies have revealed multiple ways by which viruses and bacteria 
can manipulate EV synthesis to enhance their transmission and pathogenesis (reviewed in 
(Raab-Traub and Dittmer 2017)). Conversely, EVs produced by immune cells play an 
important role in host responses to infection. One early example of this role was the finding 
that EVs from B lymphocytes contained class II major histocompatibility (MHCII)-antigen 
complexes that could activate CD4+ T cells in an antigen-specific manner (Raposo, Nijman 
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et al. 1996). Subsequent studies found that EVs of dendritic cells contained class I major 
histocompatibility (MHCI)-peptide complexes that could stimulate cytotoxic CD8+ T cell 
responses, identified cell-dependent and independent mechanisms for the antigen 
presenting activity, and identified receptor and cytokine/chemokine effects to regulate 
multiple cells involved in the adaptive immune response (Hwang, Shen et al. 2003, Nolte-
't Hoen, Buschow et al. 2009, Mittelbrunn, Gutierrez-Vazquez et al. 2011). Notably, EVs 
derived from cells infected with either viral or bacterial pathogens demonstrate several 
mechanisms to mediate the immune system, including effects to inhibit host EV effects to 
promote adaptive immune responses, indicating that better understanding of these 
mechanisms is important to improve therapeutic approaches used to treat these pathogens. 
EVs carrying pathogen-derived factors are also of interest as biomarkers of infection, since 
these factors should be more stable than soluble factors in circulation that are exposed to 
circulating hydrolase activities. EVs are also stable in circulation, are capable of packaging 
a broad array of biomolecules and small molecule drugs, and exhibit potential as selective 
targeted biogenic carriers (Clayton, Harris et al. 2003, Morse, Garst et al. 2005, Admyre, 
Bohle et al. 2007, Sun, Zhuang et al. 2010, Alvarez-Erviti, Seow et al. 2011, Tian, Li et al. 
2014, Fuhrmann, Neuer et al. 2017). Based on these properties, this review describes 
current knowledge of EV actions to promote disease and regulate host immunity, and the 
potential of these EVs as disease biomarkers and future therapeutic agents. 
1.2.1. EV regulation of immune responses 
 EVs derived from immune cells carry proteins that can regulate important aspects of 
host immunity, including T-cell activation (e.g., MHCI and MHCII, lymphocyte function-
associated antigen-1, and intercellular adhesion molecule-1, depending on the parent cell) 
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(Lee, El Andaloussi et al. 2012). MHC I and MHC II and immunomodulatory proteins are 
enriched on EVs of antigen-presenting cells (APCs; e.g., dendritic cells (DCs) and 
macrophages) (Raposo, Nijman et al. 1996) and these EVs appear capable of activating T 
cells by transferring antigens or MHC-antigen complexes to conventional APCs, or by 
directly presenting MHC-antigen complexes to T cells as APC surrogates (Thery, Duban 
et al. 2002, Hwang, Shen et al. 2003, Segura, Amigorena et al. 2005, Montecalvo, Shufesky 
et al. 2008, Qazi, Gehrmann et al. 2009). 
 For the first mechanism, evidence suggests that immature DCs that do not support 
robust immune responses secrete EVs that can transfer MHC-antigen complexes, or 
antigens, to mature DCs to activate CD4+ and CD8+ T-cell responses (Thery, Duban et al. 
2002, Andre, Chaput et al. 2004). In the so-called “cross-dressing” model, intact MHC-
antigen complexes are transferred from inactive to active DC populations (Thery, Duban 
et al. 2002, Andre, Chaput et al. 2004, Chaput, Schartz et al. 2004, Segura, Amigorena et 
al. 2005), whereas in the “cross-presentation” mechanism, mature DCs present peptides 
derived from captured EVs on their own MHC molecules (Montecalvo, Shufesky et al. 
2008, Qazi, Gehrmann et al. 2009).  
 There is also evidence that APC-derived EVs can directly activate CD4+ and CD8+ T 
cells (Utsugi-Kobukai, Fujimaki et al. 2003, Admyre, Johansson et al. 2006, Luketic, 
Delanghe et al. 2007), and stimulate both previously activated and memory T cells 
(Admyre, Bohle et al. 2007, Muntasell, Berger et al. 2007). APC-derived EVs are also able 
to directly activate naïve CD8+ T cells in vitro (Hwang, Shen et al. 2003), although they 
appear to be 10- to 20-fold less efficient than APCs, suggesting that EVs may not have a 
direct effect on naïve T cell activation in vivo. Similar studies indicate that EVs of B cells 
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can also directly present antigens to induce T cell responses (Admyre, Bohle et al. 2007), 
although with less efficiency than their parental B cells. Receptor aggregation between 
interacting T cells and DCs also creates an extended “immunological synapse” where DC-
derived EVs can directly interact with adjacent T cells in a LFA-1 (lymphocyte function-
associated antigen 1) dependent manner to promote their activation (Nolte-'t Hoen, 
Buschow et al. 2009). 
 However, while evidence indicates that EVs can directly and indirectly regulate in vitro 
CD4+ and CD8+ T cell responses, it is unclear to what extent they affect these responses 
in vivo. 
1.2.2. EV roles in infectious diseases 
 EVs released by infected cells contain pathogen- and host-derived factors, and play key 
roles in pathogen-host interactions, including pathogen uptake and replication and 
regulation of the host immune response (reviewed in (Mittelbrunn, Gutierrez-Vazquez et 
al. 2011, Schorey and Harding 2016)). For example, studies have shown that multiple 
viruses—including human immunodeficiency virus 1 (HIV-1), hepatitis viruses B, C and 
E (HBV, HCV, and HEV), and multiple members of the human herpesvirus (HHV) 
family—utilize EV ESCRT machinery for viral transmission (Pawliczek and Crump 2009, 
Sadeghipour and Mathias 2017). HIV-1, in particular, has developed several EV-mediated 
strategies to manipulate the behavior of its target cells (Garcia, Pion et al. 2005), including 
a Nef-regulated mechanism that alters EV protein trafficking in CD4+ T cells. Hepatitis A 
virus (HAV), HCV and HEV employ the EV biogenesis machinery to produce enveloped 
virions that allow the virus to avoid immune surveillance (reviewed in (Alenquer and 
Amorim 2015)). HHVs, which are responsible for a broad range of important pathologies, 
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employ endosomes to evade anti-viral immune responses through several distinct 
mechanisms that differ among these viruses (Sadeghipour and Mathias 2017). In the 
following sections, we describe how several viruses subvert the EV biogenesis machinery 
for their replication and infectivity. Much less is known about how bacteria employ the 
EVs of their host to favor their growth and survival, and most studies focus on the behavior 
of Mycobacterium tuberculosis (Mtb), an important intracellular pathogen. We will 
therefore summarize current knowledge on how Mtb regulates cellular and systemic 
processes to favor active and latent Mtb infections, and how these processes overlap with 
those of other bacterial pathogens (Figure 2). 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overview of the EV incorporation of pathogen-derived factors by the EVs of 
their host cells, including pathogen receptors and regulatory factors, to promote infection 
and pathogenesis. (A) EVs of HIV-infected cells express the HIV receptor target proteins 
CCR5 and CXCR4 and regulatory factors, including the HIV protein Nef and TAR RNA, 
among others. (B) EVs of HCV-infected cells express E2 and CD81, which promote HCV 
uptake, as well as viral RNA and host proteins (e.g., CD63) that promote HCV infections. 
(C) EVs of HBV-infected cells contain EBV RNA and proteins (e.g., LMP1) and host 
proteins (e.g., EGFR and FGF2) that promote EBV infectivity and pathogenesis. (D) EVs 
of Mtb-infected cells contain Mtb-derived glycolipids (LAM) and lipoproteins (LpqH) that 
regulate innate and acquired immune responses to promote infection.  
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1.2.3. EVs facilitate viral and bacterial pathogenesis 
 Viral and bacterial pathogens can subvert EV functions to promote pathogen 
replication, survival, or pathology. Cells employ EVs to transfer regulatory factors that 
modulate the response of local and distant cells and systemic responses. In cells with active 
viral or bacterial infections, the EV machinery can also package pathogen-derived factors 
that alter the phenotype of EV recipient cells. Many pathogen factors that are packaged 
into EVs interact with ESCRT proteins or related factors, suggesting that pathogens have 
evolved to exploit this intercellular transport and signaling pathway, using it to promote 
infection and repress anti-pathogen host responses. We discuss several examples of these 
interactions in the following sections. 
1.2.3.1. Viruses 
Functional overlaps between EV biogenesis and viral budding: Mechanisms involved in 
EV and enveloped virus budding share common features. Many retroviruses are reported 
to interact with ESCRT complex and ESCRT-related proteins involved in EV biogenesis 
through conserved protein motifs, referred to as late domains since their deletion or 
mutation leads to the arrest of virus assembly at late stages of virion synthesis (Pawliczek 
and Crump 2009). For example, HIV-1 virion interactions with TSG101, ALIX, and other 
host proteins are similar to those employed to package host proteins during EV formation 
(Gould, Booth et al. 2003). Similarities between the EV and HIV-1 packaging mechanisms 
led to the statement of “the Trojan EV hypothesis”, which proposes that HIV-1 evolved to 
utilize EV biogenesis proteins to package its capsid, while also exploiting EV uptake 
mechanisms to allow cell infection in the absence of viral envelope proteins that normally 
direct HIV-1 uptake (Gould, Booth et al. 2003). Mounting evidence suggests that several 
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human viruses hijack proteins involved in EV biogenesis to package their capsids. Human 
herpesvirus (HHV) family members exploit proteins that regulate EV biogenesis for their 
virion production. HHV-1 (herpes simplex virus 1; HSV-1) structural proteins contain 
potential TSG101 (ESCRT-I complex) and ALIX (ESCRT-I associated) binding motifs. 
Dominant-negative and siRNA expression studies also indicate that HHV-1 does not 
employ TSG101 or ALIX, but requires functional expression of CHMP (ESCRT-III 
complex) and VPS4 (ESCRT-III associated) proteins for the formation of its virion 
envelope (Pawliczek and Crump 2009, Sadeghipour and Mathias 2017). HHV-5 (human 
cytomegalovirus; HCMV) also appears to utilize a similar packaging mechanism, since 
inhibition of either CHMP1A or VPS4, but not ALIX, interferes with its virion packaging. 
Neither HHV-4 (Epstein-Barr virus; EBV) nor HHV-8 (Kaposi Sarcoma-associated 
herpesviruses) appear to require exosomal protein interactions for their secretion 
(Sadeghipour and Mathias 2017). 
 Despite these functional interactions, it is not clear how all of these viruses employ EV 
proteins in their packaging and secretion. While components of multiple viruses have been 
shown to associate with MVBs, there is little evidence that these viruses localize within 
MVBs and are secreted by MVB fusion with the plasma membrane. Only one HHV study 
appears to provide data consistent with an MVB release mechanism, reporting that HHV-
6 virions localize within MVBs in infected cells (Sadeghipour and Mathias 2017), although 
these virions (~200 nm) would be much larger than EVs (30-100 nm). 
 All members of the hepatitis virus family are reported to employ EV-related proteins 
to form enveloped virions. HBV envelope proteins colocalize with MVB proteins ALIX 
and VPS4B, and dominant-negative versions of either of these proteins block the release 
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of enveloped HBV virions  (Watanabe, Sorensen et al. 2007). HCV interacts with Hrs 
(ESCRT-0 complex) to promote apparent MVB uptake of viral capsids (Tamai, Shiina et 
al. 2012) and EVs isolated from HCV-infected hepatoma cell lines and sera of patients with 
chronic HCV infections contain HCV core and envelope proteins and full-length HCV 
RNA (Bukong, Momen-Heravi et al. 2014). HAV and HEV are shed as naked viral 
particles in feces but circulate as membrane-enclosed virions, which are less infectious but 
are masked by the host’s immune response (Sadeghipour and Mathias 2017). Recent 
evidence suggests that production of these circulating enveloped virions requires 
interaction with the exosomal sorting components CHMP2a (ESCRT-III complex), ALIX, 
and VSP4 (ESCRT-I and -III associated) for HAV (Feng, Hensley et al. 2013, McKnight, 
Xie et al. 2017) or Hrs (ESCRT-0 complex) for HEV (Nagashima, Jirintai et al. 2014). 
Similar to HHV, however, there is scarce evidence for MVB-mediated release of hepatitis 
family viruses, with only one study indicating that ~50 nm enveloped virions are detectable 
in MVBs of HEV-infected cells (Nagashima, Jirintai et al. 2014). 
 
EVs can alter virus antigenicity and infectivity: Results suggest that some persistent viruses 
(e.g., HCV and HAV) employ EVs as a strategy to escape negative selective pressure from 
neutralizing antibodies and other immune responses that act to promote viral clearance 
(Dreux, Garaigorta et al. 2012, Feng, Hensley et al. 2013, Ramakrishnaiah, Thumann et al. 
2013). MVB-mediated encapsulation may also allow a virus to spread beyond its normal 
range of cell hosts through the normal EV uptake process, as demonstrated by the ability 
of EVs containing HAV capsids to infect target cells using EV surface proteins instead of 
the EV-masked viral receptor proteins (reviewed in (Raab-Traub and Dittmer 2017)). 
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EVs can spread viral docking receptors to promote viral infectivity: HIV normally binds 
to CD4 and the chemokine receptors CCR5 or CXCR4 on target cells to mediate infection, 
and cells lacking these receptors, or with receptor mutations, are resistant to HIV infection. 
EVs secreted by HIV-infected cells contain CCR5 or CXCR4, however, and their uptake 
by cells lacking these receptors facilitates HIV infection of these otherwise HIV-resistant 
cells (Mack, Kleinschmidt et al. 2000, Rozmyslowicz, Majka et al. 2003). The widespread 
EV markers CD81 and CD63 colocalize with subgenomic HCV RNA and appear to 
promote its packaging into EVs. The HCV envelope glycoprotein E2 also colocalizes with 
CD81 and cells that internalize EVs containing this complex are more susceptible to HCV 
infection (Pileri, Uematsu et al. 1998, Ramakrishnaiah, Thumann et al. 2013). Interaction 
with this complex may also promote HCV uptake by EVs (Zhang, Randall et al. 2004, 
Chang, Hsu et al. 2017). Studies suggest that EV proteins may facilitate viral-receptor-
independent transmission of HCV and HAV, and presumably other EV-enveloped viruses, 
to uninfected cells (Ramakrishnaiah, Thumann et al. 2013, Bukong, Momen-Heravi et al. 
2014). 
 
Regulatory actions of virus-associated EVs on host cells: EVs derived from virus-infected 
cells can also transfer viral proteins to influence viral pathogenesis. EVs from HIV-infected 
cells contain the HIV-1 protein Nef, which regulates endocytosis, cytoskeletal 
rearrangement, and organelle trafficking to increase the number of EVs released from HIV-
infected cells (Ali, Huang et al. 2010, Raymond, Campbell-Sims et al. 2011), and may thus 
promote EV-mediated HIV infectivity. Nef-induction of EV-associated ADAM17 also 
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appears to promote HIV-infection of resting CD4+ T cells (Arenaccio, Chiozzini et al. 
2014), while ADAM17 and TNFα together can activate latent HIV-1 infections in primary 
CD4+ T lymphocytes and macrophages (Arenaccio, Anticoli et al. 2015). Finally, EVs 
carrying Nef appear to exert complex effects to regulate HIV-1 infection and pathogenesis 
through actions on uninfected cells (Lenassi, Cagney et al. 2010, Gray, Gabuzda et al. 
2011, Aqil, Naqvi et al. 2013), including the ability to alter the functions of import immune 
responses.  
 Human gammaherpesviruses, such as EBV, have complex effects to promote both viral 
infection and cancer. EVs derived from EBV-infected cells exploit the endosomal-
exosomal pathway to enclose both EBV- and host-derived regulatory factors (Flanagan, 
Middeldorp et al. 2003, Meckes, Gunawardena et al. 2013). In EBV-infected cells, an 
interaction between the EV protein CD63 and the viral protein LMP1 appears to promote 
LMP1 incorporation into EVs (Verweij, van Eijndhoven et al. 2011, Hurwitz, Nkosi et al. 
2017) and EVs that contain LMP1 can deliver important signaling proteins to uninfected 
cells (Meckes, Gunawardena et al. 2013). LMP1 also induces the expression of both 
epidermal growth factor receptor (EGFR) and fibroblast growth factor 2 (FGF2), which are 
also packaged in LMP-1-marked EVs (Ceccarelli, Visco et al. 2007, Meckes, Shair et al. 
2010), suggesting that EV-mediated transfer of these receptors may stimulate the growth 
of recipient cells with a potential to promote EBV-mediated tumor development.  
 
Effects of virus-associated EVs to inhibit anti-viral responses: Viruses employ several EV-
mediated strategies to attenuate host immune responses. EVs of HIV-infected macrophages 
deliver Nef to recipient cells to alter their immune function. Nef is associated with 
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intracellular sorting and trafficking pathways that promote the lysosomal degradation of 
CD4 and MHCI to reduce their surface expression (Schaefer, Wonderlich et al. 2008, Gray, 
Gabuzda et al. 2011), rendering cells that express Nef less susceptible to cytotoxic immune 
responses. Evidence also indicates that Nef+ EVs facilitate HIV pathogenesis by 
conditioning their target cells to undergo apoptosis, promoting CD4+ T cell depletion and 
HIV-mediated immune suppression to reduce immune clearance of HIV-infected cells 
(Nguyen, Booth et al. 2003, Lenassi, Cagney et al. 2010, Lenassi, Cagney et al. 2010).  
 The major EBV oncoprotein LMP1, which is carried by EVs of EBV-infected cells, 
plays an important role in EBV infection (reviewed in (Raab-Traub and Dittmer 2017)). 
LMP1 expression has an important function to activate B cells; however, recent work 
suggests that EVs carrying LMP1 may also promote B cell activation and proliferation 
(Gutzeit, Nagy et al. 2014) and can inhibit proliferation of T cells and the ability of natural 
killer (NK) cells to exert cytotoxic effects. (Flanagan, Middeldorp et al. 2003, Meckes, 
Shair et al. 2010). EBV also encodes a number of miRNAs that can modify the 
transcriptome of infected cells, and non-infected cells via EV transfer (Pfeffer, Zavolan et 
al. 2004, Yang, Huang et al. 2013). EBV-infected cells release EVs containing EBV 
miRNAs that suppress EBV target genes, including CXCL11, an immunoregulatory gene 
involved in antiviral activity (Pegtel, Cosmopoulos et al. 2010). EVs released by EBV-
infected cells also contain the host-derived protein galectin-9, which is known to induce 
apoptosis of EBV-specific CD4+ T cells through an interaction with immunoglobulin 
mucin-3, and to negatively regulate both macrophage and T cell activation (Klibi, Niki et 
al. 2009). 
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 Viruses thus appear to employ multiple EV-based mechanisms to suppress the 
clearance of their host cells by the immune system to promote continued viral infections; 
however, the in vivo relevance of these mechanisms is not clear.  
 
Viral transfer through immune cell EVs: In addition to actions to inhibit the antiviral 
activity of immune cells, virus-derived EVs can also use these cells to promote viral 
transfer to new host cells. HIV-1 virions captured by immature DCs and exocytosed in 
association with the DC cell’s EVs can trans-infect CD4+ T cells (Wiley and Gummuluru 
2006). The Trojan horse hypothesis of HIV-1 trans-infection (Gould, Booth et al. 2003, 
Izquierdo-Useros, Naranjo-Gomez et al. 2010) takes this further, suggesting that HIV-1 
virions are retained in the MVB compartment of mature DCs and trans-infect CD4+ T cells 
in lymph nodes by following the same trafficking pathway that DC EVs use to disseminate 
antigens (Gould, Booth et al. 2003, Izquierdo-Useros, Naranjo-Gomez et al. 2010, 
Narayanan, Iordanskiy et al. 2013). 
1.2.3.2. Bacteria 
Regulatory actions of bacterial-associated EVs on host cells: Bacterial pathogens can be 
classified based on the nature of their interactions with their host, including whether they 
prefer or require an intracellular or extracellular niche to initiate and maintain active 
infections. Both extracellular and intracellular bacteria can display complicated lifecycles, 
but intracellular bacteria have several unique options to subvert cellular processes, 
including the EV pathway, to promote their growth and survival. Mycobacterium 
tuberculosis is perhaps the best studied of these pathogens with respect to its EV effects 
due to its significant worldwide impact on public health, although several other 
                                                                                                                      
 
17 
intracellular pathogens are responsible for significant human diseases. M. tuberculosis 
(Mtb) evades the innate immune response by stably infecting phagocytic cells, such as 
macrophages, which are primarily responsible for clearance of microbial pathogens. Mtb 
lipoproteins and lipoglycans inhibit phagosome maturation, generating a stable 
intracellular niche for the engulfed Mtb bacilli and blocking MHCII-antigen complex 
cycling to the cell surface to inhibit the host response to Mtb-derived antigens (Beatty and 
Russell 2000, Beatty, Ullrich et al. 2001). Mtb-derived factors can also promote EV release 
and it is hypothesized that some mycobacterial proteins contain signals that direct them to 
MVBs to promote their incorporation into EV (Giri, Kruh et al. 2010). 
 Mtb-related EVs play important roles in regulating the phenotypes of both infected and 
uninfected cells and likely contribute to the overall pathogenesis of Mtb infections (Beatty 
and Russell 2000, Beatty, Ullrich et al. 2001). EVs of Mtb-infected macrophages can 
stimulate non-infected macrophages to secrete chemokines to induce the migration of naïve 
T-cells and macrophages (Singh, Smith et al. 2012). Mice intranasally injected with EVs 
from Mtb and M. bovis BCG, revealed increased TNFα and IL-12 production, as well as 
the recruitment of macrophages and neutrophils to the lung (Bhatnagar, Shinagawa et al. 
2007), suggesting that these EVs could recruit non-infected target cells to promote disease 
progression. Macrophages infected with M. avium also revealed increased EV secretion, 
which leads to a pro-inflammatory response in non-infected macrophages while 
simultaneously downregulating a number of IFN-γ-inducible genes in naïve cells to inhibit 
the inducible expression of MHC-II and the CD64 immunoglobulin receptor (Bhatnagar 
and Schorey 2007). Macrophages infected with M. avium and M. smegmatis exhibited 
increased EV secretion and increased EV expression of HSP70 to promote in vitro 
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macrophage activation and TNFα expression (Anand, Anand et al. 2010). EVs of Mtb-
infected cells also contain the 19 kDa lipoprotein LpqH, which can promote inflammation 
and stimulate in vitro macrophage activation and TNF-α expression via the Toll-like 
receptor/MyD88 pathway (reviewed in (Schorey and Bhatnagar 2008)). These results 
suggest that EVs from mycobacterium-infected cells can both activate and recruit immune 
cells, and may therefore influence innate and acquired immune responses during 
mycobacterial infection (Bhatnagar, Shinagawa et al. 2007), although the relative impact 
of such putative effects on the overall immune response is not clear. 
Effects of bacterial-associated EVs to inhibit anti-bacterial immune responses: EVs 
released by macrophages infected with Mtb bacilli contain protein cargos that regulate both 
innate and adaptive immune responses. EVs from Mtb-infected macrophages contain the 
glycolipid lipoarabinomannan (LAM) that inhibits T cell receptor signaling and T cell 
activation responses, which may induce immune suppressive mechanisms that promote the 
survival of Mtb-infected cells to maintain active Mtb infections (Mahon, Sande et al. 2012, 
Yang, Ruffner et al. 2012). EVs from Mtb-infected cells can partially suppress the ability 
of macrophages to respond to INF-γ to inhibit macrophage APC function (Harding and 
Boom 2010). EVs of macrophages infected with M. avium can also downregulate a number 
of IFN-γ-inducible genes in naïve cells to inhibit the inducible expression of MHC-II and 
the CD64 immunoglobulin receptor (Bhatnagar and Schorey 2007). 
These results suggest that exosomes from mycobacterial-infected cells can promote 
both the recruitment and the activation of the immune cells, and thus may play a key role 
in the innate and acquired immune responses during mycobacterial infection (Bhatnagar, 
Shinagawa et al. 2007). 
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1.3. The emergency of liquid biopsy in cancer diagnostics 
Tumor biopsy is considered the gold standards for detection and routine monitoring of 
cancer progression. However, their invasiveness, along with tumor sampling brings about 
challenges with studying tumor heterogeneity and evolution, making it an unlikely process 
for regular monitoring (Vaidyanathan, Soon et al. 2019). Recently, liquid biopsy samples, 
including plasma/serum, saliva, and urine, are of great interest as a means to reduce barriers 
to the rapid evaluation and treatment of diseases, including most cancers, where it is not 
feasible to obtain biopsies or repeat biopsies from the disease site. Such biopsies methods 
have influenced the development of several therapies that require routine measurements of 
essential biomarkers (Sharma, Zuniga et al. 2017, Vaidyanathan, Soon et al. 2019). 
Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are biomarkers 
present in blood known to be released from cells within the primary tumor and play a key 
role in metastasis. However, their low availability (1–10 circulating tumor cells [CTCs]/mL 
of blood) and difficulty in enrichment makes them an unfavorable candidate for cancer 
detection and prognosis (Herreros-Villanueva and Bujanda 2016).  
EVs on the other hand, are stable membraneous vesicles , ranging from 30-100 nm in 
diameter released by cells and present in all bodily fluids with concentrations of > 1010 
vesicles / mL in blood, (Keller, Ridinger et al. 2011, Lee, Fraser et al. 2018), making EVs 
highly abundant and easily available biomarkers (Nuzhat, Kinhal et al. 2017, Rajagopal 
and Harikumar 2018, Rodrigues, Fan et al. 2018, van Niel, D'Angelo et al. 2018). Critical 
information is stored in the molecular profile of the exosomal cargo and surface expression 
due to their endocytotic biogenesis from parent tumor cells making them favorable for 
studying tumor microenvironment (Kalluri 2016). However, being smaller than cells (10-
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30μm) and larger than proteins makes it very difficult to isolate these EVs (Vaidyanathan, 
Soon et al. 2019). The conventionally available analytical tools are time-consuming, 
require extensive pre-treatments like (ultracentrifugation), quantification (Nanosight) , 
have low yield and hard to optimize, making it difficult for its use in clinical EV research 
environment (Thery, Amigorena et al. 2006, Dragovic, Gardiner et al. 2011) . Current new 
technologies are able to circumvent the conventional process for EVs isolation and 
purification by developing methods that can improve isolation efficiency and specificity 
from bodily fluids but have a lower throughput which needs to be addressed to have a more 
practical use (Shao, Im et al. 2018). 
1.4. Variable abundance of EVs in diseased conditions 
There are several studies focusing on how EVs release rate changes based on 
different pathological conditions, and how not only the total protein levels but also the 
contents of individual proteins in EVs can play a role in providing prognostic information 
(Whiteside 2016). Thus having knowledge of the amount of EVs present in plasma or 
serum acts as crucial information during biomarker readout as it can influence the absolute 
measurement of the expression levels of markers under consideration. For instance, 
findings suggested that plasma EVs levels were increased in HIV-positive subjects which 
correlated with increased oxidative stress and decreased polyunsaturated fatty acids. On 
further evaluation, they did not see any clear relationship to virological and immunological 
parameters in treated patients with suppressed viral load (Chettimada, Lorenz et al. 2018), 
likewise another study revealed increased levels of plasma EV- associated alpha-synuclein 
(α-syn) in Parkinson’s disease which could reflect a mechanism to release α-syn under 
conditions of cellular stress and relatively increased α-syn concentrations (Shi, Liu et al. 
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2014). A number of studies in cardiovascular-related disorders have demonstrated 
increasing levels of circulating EVs in insulin-resistant patients, patients with type-2 
diabetes along with a further increase in these levels with microvascular complications. 
There are studies showing increased levels of EVs are an indication of cardiovascular 
disorders including, atherosclerosis, hypertension and following a stroke or myocardial 
infarction (Charlotte, Jose et al. 2016). 
 In cancer alone, the EVs release can be affected by several underlying conditions 
present in tumor microenvironment such as hypoxia, change in intracellular to intercellular 
pH levels, or even overexpression of an enzyme such as heparanase (Parolini, Federici et 
al. 2009, King, Michael et al. 2012, Thompson, Purushothaman et al. 2013, Zhang, Yuan 
et al. 2015). EVs are also increased in many inflammatory conditions, there were studies 
focusing on the relationship between inflammation and kidney diseases which revealed 
that in mice with acute and chronic kidney injury showed an increase in levels of exosomes 
carrying the inflammatory chemokine mRNA in mice  (Console, Scalise et al. 2019). Apart 
from underlying pathological conditions impacting the release rate of EVs, this change is 
even observed in normal healthy pregnancy. The number of EVs present in the maternal 
plasma increased significantly in the gestational age across the first trimester of pregnancy. 
Along with observations wherein there were increased concentrations of EVs in women 
with full-term pregnancies that those from pregnancies delivery pre-term (Sarker, Scholz-
Romero et al. 2014). Further emphasizing how a change in the number of EVs in a sample 
could influence the expression levels of biomarkers under observation.  
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1.5. Influence of marker expression levels in EVs 
Over the past decade surface protein expression levels on circulating tumor EVs 
are of particular interest in providing valuable information in regards to the physiological 
states of parental cells, along with playing a significant role in developing prognosis for 
potential metastasis and decision making for deciding the route for treatment (Xu, Rai et 
al. 2018).  While performing these measurements there is an increasing need to know 
whether there is a significant change in exosomal marker expression levels, either 
overexpression or suppressed expression in individual EVs. A recent study on exosomal 
PD-L1 expression demonstrated increased levels in circulating EVs that correlated with 
tumor size. Further investigations revealed that stimulation with interferon-γ (IFN-γ) 
increased the amount of PD-L1 on EVs, which suppresses the functions of CD8 T cells and 
promotes tumor growth. A similar increase was observed in patients with metastatic 
melanoma and varied during the course of anti-PD-1 therapy. This increase during early 
stages of treatment indicates how this information could be used as an indicator for disease 
detection and monitoring. To strengthen the point there were making, they showed that 
there was no or only marginal difference in the number of circulating EVs, and the increase 
in levels of PD-L1 was a change in the expression levels of the marker on these EVs (Chen, 
Huang et al. 2018). 
  There were other studies that revealed exosomal uptake by organ-specific cells 
can prepare pre-metastatic niches based on the distinct EVs integrin expression levels 
and could help in predicting organ-specific metastasis. They study integrins α6β4 and 
α6β1 were associated with lung metastasis, while exosomal integrin αvβ5 was linked to 
liver metastasis. Additionally, they showed these integrin expression levels could 
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predict lung and liver metastasis and that exosomal integrin expression did not reflect 
cellular expression, thus emphasizing how exosomal integrin expression alone could 
help predict organ-specific metastasis.(Hoshino, Costa-Silva et al. 2015).  
 A recent study focused on the effects of increased endogenous levels of 
transcription factor Hypoxia-inducible factor-1α (HIF-1α) in nasopharyngeal carcinoma 
associated latent membrane protein 1(LMP1) positive EVs.  HIF-1α mediates cellular 
responses to hypoxia and transcriptionally regulate over 40 genes that are involved in tumor 
development and progression, along with increased proliferation rate and invasiveness.  
Whereas, LMP1 is the oncoprotein of Epstein - Barr virus (EBV) that drives oncogenic 
processes by promoting tumor progression by enhancing the expression of invasion and 
metastatic factors. They showed that LMP1 positive EVs containing HIF-1 α can have 
reciprocal changes in the expression factors associated with the epithelial-mesenchymal 
transition (EMT) pathways , along with pro-metastatic effects in recipient cells by making 
non-malignant nasopharyngeal cells more invasive (Aga, Bentz et al. 2014, Sarker, Scholz-
Romero et al. 2014).  
These above studies accentuate the increasing need to know EV protein expression 
levels, and how that information can help understand tumor progression, metastatic niches, 
and responses to treatment. Therefore, in order to understand the expression change of 
markers in EVs, we need to have a way to understand the starting sample population and 
take that into consideration when measuring biomarker readout, as absolute readout 
could blind us and fail to understand the underlying process and its effects in a diseased 
condition. 
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1.6. Motivation and Significance 
Circulating levels of a disease-associated EV biomarker can thus reflect both the 
release rate of disease-associated EVs from the target tissue and their relative expression 
of the target biomarker, which are regulated by different processes. This critical difference 
is not addressed by standard EV analyses unless a study protocol also quantifies the number 
of target EVs in an analysis sample. As part of my doctoral work, we tried to tackle the 
problem of quantifying EVs in sample and measuring the relative expression levels of 
markers in EVs by developing a fluorescence-based assay that can measure the number of 
EVs and the total protein readout of EV surface markers.   
We established a method where EVs derived from two pancreatic cell lines were 
captured and immobilized on the surface of a 96-well plate with an antibody specific for 
the common EV membrane protein CD81 (Kowal, Arras et al. 2016) and stained the EV 
population with a lipophilic dye that labeled the EV lipid bilayer to provide a quantitative 
readout reflecting the total number of EVs in the sample. These EVs were then 
hybridized with quantum dot-labeled antibody probes specific to target EV biomarkers 
and signal from the bound probes was normalized to the lipophilic dye signal to 
determine the mean EV expression of these biomarkers in the analyzed sample. This 
novel assay utilized multiplexed fluorescent signals from specific antibody-labeled 
quantum dots to measure EV expression of two cancer-associated biomarkers – epithelial 
cell adhesion molecule (EpCAM) and Ephrin type-A receptor 2 (EphA2) – on pancreatic 
cancer cell-derived EVs (Figure 3). The approach revealed linearity for the sample between 
normal and cancer cell lines for both EpCAM and EphA2 expression. Furthermore, the 
normalized signal showed a similar protein expression level for EVs from the same cell 
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type. This approach circumvents the need for separate EV isolation, purification and 
quantification steps, which are time-consuming, low-throughput, require expensive and 
specialized equipment, and are difficult to optimize, rendering them unsuitable for 
clinical translation (Thery, Amigorena et al. 2006, Dragovic, Gardiner et al. 2011) 
 
Figure 3. Schematic of the quantum dot (Qdot Assay). EVs captured by an antibody to an 
EV-specific surface are stained with the lipophilic fluorescent dye DiO and then hybridized 
with antibody-conjugated quantum dot probes specific for biomarker targets on the EV 
membrane (e.g., EpCAM and EphA2). DiO signal from the captured EVs functions as a 
surrogate marker of EV abundance and allows direct normalization of quantum dot probe 
signal to permit quantification of mean biomarker levels in a captured population without 
the need for an independent EV isolation and quantitation procedure. This allows direct 
comparison of relative EV biomarker levels among different cohorts for disease diagnosis 
(e.g., cancer patients vs. non- cancer).  
We further performed clinical validation on two cancer cohort. One comprised of 
plasma samples collected and tested for a pancreatic cancer cohort (n=74; Control =21, 
Stage I\II = 11, Stage III = 21 , Stage IV=21) which revealed robust sensitivity and linearity 
for the detection of individual EV expression levels, which distinguished cancer and 
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normal subjects for both markers – EpCAM and EphA2. The second consisted of serum 
samples collected for pancreatic cancer cohort (n= 20; Non-Cancer = 7, Cancer = 9 and 
Metastasis = 4) showing significant difference for the two marker EpCAM and EphA2 for 
cancer vs non- cancer group , which further significantly increased after normalizing the 
signal of the markers to the number of EVs present. Notably, this assay approach analyzes 
EVs directly captured from serum/plasma without the need for purification steps or 
quantification, utilizing a fluorescence-based workflow that is suitable for clinical 
translation, and employs a format in which disease specificity can be altered by shifting 
the detection probe (quantum dots) specificity.  
1.7. Organization of the dissertation 
The aim of the dissertation was to design and develop and immuno-based 
fluorescent assay which allows EV capture, followed with quantifying the number of EV 
and finally measuring the total expression of two cancer specific surface markers on the 
EVs. Finally, the signal from the bound probes for EV biomarker was normalized to the 
lipophilic dye signal to determine the mean EV expression of these biomarkers. The 
dissertation captures the proposed concept as follows: 
i. Normalization using fluorescent dye : Demonstrating the use of a fluorescent lipophilic 
lipid membrane dye (DiO) to measure EV abundance in different sample populations. 
Chapter 2 will focus on variable abundance of EVs as observed in cancer cells and 
the need to know the number of EVs in a sample when studying the total expression 
levels of surface markers. In chapter 3, we focus on developing a method that will label 
the EVs and measure the qualitative signal for the total amount of EVs in a sample. We 
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used a fluorescent lipid dye which would bind to the membrane of the capture EVs on a 
96-well black plate. Labeling EVs bound to a solid substrate eliminates the need for 
sample washing and ultracentrifugation to get rid of unbound dye. 
ii. Analytical Validation : Development and analytical validation of the quantum dot assay 
(Qdot Assay) for multiplexed detection of cancer-specific surface markers on EVs 
 Chapter 4 focuses on testing and validating the two markers, EpCAM and EphA2 
to help distinguish between normal and cancer-derived EVs. Followed with chapter 5, 
where we, determine the detection probes in our assay by conjugating the quantum dots 
with EpCAM and EphA2. In addition to testing the assay for multiplexed detection of the 
total protein levels by measuring the total quantum dot signal. Finally, we present our proof 
of concept, by normalizing our total protein signal with the DiO signal for total EVs to 
measure individual EV protein expression levels. 
iii. Clinical Validation : Performing the quantum dot assay on a clinically relevant cancer 
cohort 
Chapter 6 is the clinical validation of the assay where we test the significance of 
the Qdot assay in two different clinically relevant pancreatic cancer/ cancer cohort. In the 
first study, we analyzed DiO-normalized anti-EpCAM-QD605 and anti-EphA2-QD655 
probe signal on CD81-captured EVs from serum samples drawn from a cohort of 35 
subjects that included non-cancer control subjects having other disease conditions like liver 
injury, pancreatitis and cholangitis (n=14)  and pancreatic cancer patients (n=21).   In the 
second study, we tested in total 74 subjects that included healthy non-malignant control 
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subjects, and pancreatic cancer patients with stage I/II, III, or IV tumors (11 – 21 
subjects/group). 
1.8 Significant Contributions 
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• Amrollahi, Pouya;  Rodrigues, Meryl; Lyon, Christopher J; Goel, Ajay, Han, 
Haiyong; Hu, Tony Ye ;“Ultra-Sensitive Detection of Cancer: Methodology, 
Mechanism, and Applications” , Frontiers in Genetics 
Published Manuscript: 
• Rodrigues, Meryl; Fan, Jia; Lyon, Christopher J; Wan, Meihua, Ye Hu, “Role of 
Extracellular Vesicles in viral and bacterial infections: Pathogenesis, Diagnosis and 
Therapeutics,” Theranostics, 2018; 8 (10):2709–2721. Published 2018 Apr 9. 
doi:10.7150/thno.20576  
Conference presentations: 
• Meryl Rodrigues, Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li 
Y, Yokoi K, Katz MH, Koay EJ, Zhao Z, Hu Y, “Nanoplasmonic Quantification of 
Tumor-Derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and 
Treatment Monitoring” World Pharma Week, Boston, Poster presentation   
 
                                                                                                                      
 
29 
CHAPTER  
2 VALIDATING THE HYPOTHESIS OF VARIABLE ABUNDANCE OF EVS 
DERIVED FROM CANCER CELLS 
2.1 Introduction 
EV biogenesis in enhanced in cancer, where tumor cells produce and secrete more 
EVs than normal proliferating cells (Atay and Godwin 2014) . EV levels in plasma and 
other body fluids of patients with cancer are frequently elevated (Melo, Sugimoto et al. 
2014, Melo, Luecke et al. 2015, Kalluri 2016). This shows that EV biogenesis is enhanced 
in cancer; and especially that tumor cells can produce and secrete many more EVs than 
normal proliferating cells (Taylor and Gercel-Taylor 2008, Dabitao, Margolick et al. 2011, 
Melo, Luecke et al. 2015). The underlying reason for this increase in EV release is still 
unclear, however, it is speculated that one reason could be the altered cellular physiology 
during pathological conditions like cancer (Kalluri 2016). 
Several studies have been performed to understand the underlying reasons for the 
increase in the number of EVs released in cancer. There are studies showing that stress, 
including hypoxia prevalent in a tumor microenvironment, accounts for an increase in EV 
secretion by tumor cells (King, Michael et al. 2012). Additionally, intracellular and 
intercellular pH can affect EV release rate. Low pH condition is a hallmark of tumor 
malignancy. It is observed that when the microenvironmental pH is low, EV secretion and 
uptake by recipient cells is increased (Parolini, Federici et al. 2009). There is evidence that 
oncogenes and tumor suppressors regulate EV secretion in cancer. It was demonstrated that 
p53- regulated protein tumor suppressor-activated pathway 6 (TSAP6) induces EV 
secretion under stressed conditions (Yu, May et al. 2005, Yu, Harris et al. 2006). 
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Heparanase, an enzyme overexpressed in many tumor cell lines, was reported to regulate 
EV secretion (Thompson, Purushothaman et al. 2013). Although there are many insights 
suggesting several different mechanisms that may be involved in EV release, it seems that 
it may depend heavily on the cancer type and its aggressiveness. Several studies show that 
the number of EVs released can increase as time increases, but the reason behind it is still 
unknown. There are studies showing that EV concentration has been elevated in the 
systemic circulation of patients with ovarian, breast, and pancreatic cancer. However, one 
must account for the fact that in these studies, there were instances when EVs increased as 
tumor size increased, or the EV concentration increased as a natural extension of cancer 
stage progression (Taylor and Gercel-Taylor 2008, Melo, Luecke et al. 2015). 
2.2. Materials and Methods 
We designed an experiment to culture and quantify the number of EVs released 
from normal vs cancer cells. In this study, we collected EVs from two pancreatic cell lines, 
pancreatic cancer cell line (PANC1) and a normal pancreatic cell line (HPNE) 
1. Cell Culture. The human pancreatic cancer cell line PANC-1 and the non-malignant 
human pancreas cell line HPNE were obtained from American Type Culture Collection 
(Manassas, VA). PANC1 and HPNE cell lines were grown at 37oC in a humidified 5% 
CO2 incubator in RPMI-1640 (Gibco, Life Technologies) or DMEM (Gibco, Life 
Technologies) medium, respectively, and supplemented with 10% fetal bovine serum 
(FBS), penicillin (1U), and streptomycin (1 μg/mL).  
2. EV Isolation, and quantification. Cells were incubated with media containing 10% FBS 
for a minimum of 48 hours prior, then washed twice with PBS (pH 7.0), and incubated 
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in FBS-free media for 48 hours, after which the media was collected and centrifuged 
at 400 g for 20 minutes and the resulting supernatant was passed through a 0.45 µm 
filter to remove cell debris. This sample was then concentrated with a 100k MWCO 
filter (Merck Millipore Ltd.), centrifuged at 110,000 g for 2 hours, and the EV pellet 
was suspended in PBS and stored at 4oC until use (< 2 weeks). EV size distributions 
and EV concentrations of HPNE and PANC-1 EV samples were analyzed using a 
NanoSight LM10 instrument and Nanoparticle Tracking Analysis Software (Malvern 
Instruments). 
2.3 Results and discussions 
We performed a  comparative study on the number of cells vs the number of EVs  
released from PANC-1 and HPNE cell lines at three different time points. All culture 
conditions between the two populations were maintained in order to have a fair 
comparison. The data was collected after the cells had reached 90% confluency, where in 
the culture media was then replaced with serum-free media for EV collection. Following 
the standard protocol for the EV isolation, purification, and isolation, both cells and EVs 
were collected at three-time points 24 h, 48 h and 72 h. The total number of cells was 
calculated using a cell counter and the number of EVs using the nanosight instrument. 
The same number of cells were seeded during the start of the experiment and by 
monitoring the growth of these cells, we managed to have the same number of cells at the 
three-time points for both HPNE and PANC-1., we can see there is no significant difference 
between the total number of cells collected at the three time points, stating that we could 
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now perform a comparative study on the number of EVs that would be released from these 
cells (Figure 4).  
The EVs were isolated from cell culture supernatants by ultracentrifugation and 
analyzed by NanoSight, nanoparticle tracking analysis at 24, 48 and 72 h. respectively. The 
NanoSight instrument reveals number of vesicles along with the size distribution for each 
sample. HPNE shows EVs being released post 24 h, and then there isn’t an increase for the 
next 48 h. or 72 h. time point (Figure 5). However, in PANC1 cells, the EVs released is 
noticed at 24 h., but following that there is still an increase in the total number of EVs for 
48 h. and 72 h. time points. On comparing the number of EVs at these time points, they 
were significantly higher in PANC-1 compared to HPNE , with p-values 0.0019 for 24 h, 
0.0011 for 48 h and <0.001 for 72 h with 95% confidence interval. 
   
Figure 4. The comparison between the number of cells for both PANC-1 and HPNE at the 
three time points. There is no significant difference observed, stating that the number of 
EV collected from these samples comes from the same number of cells at 24, 48 and 72 h. 
respectively. 
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On further analyzing the data collected, we examined the per cell EV release 
(Figure 6), which suggests that the same number of cells in both populations can release 
different number of EVs which confirms the hypothesis that EV secretion rates are could 
be altered by multiple reasons, and that the number of EVs released can be different even 
after they adjust for the growth increase in total number of cells at that time. 
     
Figure 5.The total number of EVs released from same number of PANC-1is more than 
HPNE cells for the three different time points. (** p<0.01, *** p<0.001, *** p<0.001, 
****p<0.0001 by Student’s t-test) 
    
Figure 6. The per cell number of EVs released for PANC-1 is more than HPNE cells, and 
this difference increasing significantly as the time increases. (** p<0.01, *** p<0.001, *** 
p<0.001, ****p<0.0001 by Student’s t-test) 
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CHAPTER  
3 NORMALIZATION USING A FLUORESCENT LIPID DYE 
3.1. Introduction 
 Despite increasing scientific and clinical interest in the potential of EVs for disease 
diagnosis, there are few standard procedures for their isolation, detection, characterization 
and quantification. The International Society for Extracellular Vesicles (ISEV) has 
emphasized the development and harmonization of standard protocols for specimen 
handling, isolation and analysis to facilitate comparison of results achieved within this fast-
growing field (Witwer, Buzas et al. 2013, Lener, Gimona et al. 2015). EVs are too small 
to analyze by conventional optical detection methods, and their low refractive index and 
heterogeneous size and composition complicate such analyses, but recent advances now 
allow nanoparticle quantitation, which is useful for general EV analyses. 
Current EV studies are focusing on quantifying the number of EVs when 
studying biomarker expression levels (Chen, Huang et al. 2018, Shao, Im et al. 2018). 
However, in-order to integrate it into the analysis platform, it needs a study protocol that 
would require to quantify the number of target EVs in an analysis sample. The 
quantification methods require purified sample, as there are abundant factors in serum, 
plasma, and other body fluids that interfere with these analyses along with large volume 
for sample preparation making it not practical for most clinical setting. Some of the current 
quantification methods is further discussed in the following section. 
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3.1.1. Technologies for quantifying EVs 
3.1.1.1. Transmission electron microscopy (TEM)  
 Transmission electron microscopy can visualize EVs (Yuana, Koning et al. 2013) and 
analyze size and morphology, but not concentration, and overlap of the EV size range with 
those of several easily detectable contaminants (e.g., immune complexes, liposomes, 
calcium-phosphate micro precipitates and other particles) may introduce artifacts. This 
method is labor intensive and requires the use of procedures that are expensive and 
impractical for clinical use. More importantly, while it can potentially be conjugated with 
immune-gold staining to visualize specific EV sub-types, it cannot cope with the challenge 
of identifying and quantitating disease-associated EVs amidst the diverse population of 
EVs, particularly during early disease progression when these EVs should be extremely 
rare in the highly abundant circulating EV population. 
3.1.1.2. Nanoparticle tracking analysis (NTA)  
 Nanoparticle tracking analysis (NTA) is an optical particle based tracking mechanism 
which employs a laser beam to illuminate all vesicles in a sample suspension, a light 
microscope to record the scattered light, and software to measure vesicle sizes as 
determined by the Brownian motion track of each particle (Dragovic, Gardiner et al. 2011, 
Vogel, Willmott et al. 2011). These instruments are commercially available and can 
measure the number and absolute size distribution of vesicles in a solution, and quantitate 
EVs based on their unique size profile but however need accurate camera and analysis 
setting to employ proper readings.  
3.1.1.3. Tunable Resistive pulse sensing (RPS)  
  Resistive pulse sensing (TRPS) is another alternative method to the NTA, that can 
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determine the absolute size distribution of vesicles in sample suspensions via the Coulter 
principle (Kozak, Anderson et al. 2012), and at least one company has developed an 
instrument to exploit this approach. This system consists of two fluid cells divided by a 
non-conductive nanoporous membrane. A particle moving through one of these nanopores 
in response to a voltage applied across the cell membrane alters the ion flow, resulting in a 
brief “resistive pulse”, which is recorded for calculation against a reference standard made 
with beads of known diameter and concentration (Vogel, Willmott et al. 2011, Kozak, 
Anderson et al. 2012).  
3.1.1.4. Alternating current electrokinetic microarray chip (ACE) 
 Current technologies are trying to focus on integrating the isolation of these EVs on a 
single platform. In 2017, a group addressed this issue by developing alternating current 
electrokinetic (ACE) microarrays can isolate EVs from plasma samples followed with on-
chip immunofluorescent detection of EV proteins and provide mRNA for downstream RT-
PCR analysis (Ibsen, Wright et al. 2017), providing a potential means to isolate and analyze 
total EV populations without a separate EV isolation step. However, none of these 
approaches are yet available for clinical applications, but they demonstrate the potential of 
new chip technologies to rapidly profile disease-specific EVs from human samples after 
minimal sample preparation 
3.1.2. Variable exosomal cargo – DNA, RNA, and proteins 
 To address this issue of quantifying EVs and bi-passing the conventional route, we 
focused on using fluorescent dyes to help quantitate the EVs in our study. There are several 
studies showing their use in exosomal localization, uptake and transfer studies (Hood, San 
et al. 2011, Chen, Wang et al. 2013, Kanwar, Dunlay et al. 2014, Mendt, Kamerkar et al. 
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2018). Fluorescent labeling of  EV cargo components such as RNA, DNA, or protein could 
be used as a source for relative EV abundance in highly defined and homogeneous EV 
samples (Li, Zeringer et al. 2014, Williams, Rodriguez-Barrueco et al. 2014, Xu, Rai et al. 
2018), such as purified cell culture-derived EVs samples. However, in 2014 a group 
focused on studying the presence of double-stranded DNA in tumor-derived EVs (Thakur, 
Zhang et al. 2014). They revealed that this exosomal DNA represent the entire genome and 
emulate the mutations seen in parental tumor cells. Furthermore, they looked at the 
exosomal DNA contents from various cancer cell lines including melanoma, breast, and 
lung, prostate and pancreatic cancer. They saw variable amounts of exosomal DNA, where 
in these levels were lowered in pancreatic and lung cancer cell lines, suggesting difference 
in exosomal DNA packaging among different cancer models. Exosomal cargo is known to 
contain RNA that play a role in wide range of biological functions, right from cell to cell 
communication to different signaling pathways. Another recent study revealed variable 
amounts of RNA present on EV isolated from serum versus urine EVs (Li, Zeringer et al. 
2014). They studied the amount of RNA present in these EVs and noted that the theoretical 
values did not match the values observed for these EVs, suggesting that EVs have a very 
heterogeneous population with variable RNA contents based on packaging of these 
molecules and hence some EV might contain substantially lower amount of RNA in 
comparison to other EVs.  
 Comprehensive protein profiling studies revealed the difference in the cargo between 
EVs, suggesting that during biogenesis there is selective enrichment of these molecules in 
EVs. To sum it up EV biogenesis is a complex process and several underlying processes 
that are either parent cell related or other signaling and pathological stimuli that the cell 
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could undergo can influence exosomal cargo (van Niel, D'Angelo et al. 2018) further 
stating that labelling these biomolecules is not feasible with EV populations found in 
complex biological samples and body fluids, since changes in the relative abundance of 
EVs with different cargo compositions can skew such normalizations. Looking back at EV 
biogenesis process which occurs via endocytosis for majority of the cell types, which 
includes the dual invagination processes, first by the inward budding of the plasma 
membrane followed with invagination of the early endosome membrane, states that the 
plasma membrane is the universally present characteristic feature within all EVs (Xu, 
Rai et al. 2018). We exploited this common feature where the mean EVs lipid content of 
a mixed population should significantly change only in response to a marked change in the 
mean EV diameter of the sample. Since lipophilic dyes have been employed in EV 
localization, uptake and transfer studies (Hood, San et al. 2011, Chen, Wang et al. 2013, 
Kanwar, Dunlay et al. 2014, Mendt, Kamerkar et al. 2018), we hypothesized that 
quantifying the signal from EVs stained with such a dye could serve as a surrogate marker 
of EV abundance. 
3.2. Material and methods 
 The experiments were designed to test and validate the use of lipophilic lipid dye as a 
normalizer for the assay. The goal of the experiments was to culture, isolate and quantitate 
purified EVs using the nanosight, followed with labeling known amounts of both HPNE 
and PANC-1 EVs to measure the labeling efficiency of the lipid dye. Once we confirmed 
the use of the dye as a normalizer, we then incorporated the dye with the quantum dot assay 
using by testing it on the 96-well black plate. 
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3.2.1. EV Isolation, and quantification 
 Cells were incubated with media containing 10% FBS for a minimum of 48 hours prior, 
then washed twice with PBS (pH 7.0), and incubated in FBS-free media for 48 hours, after 
which the media was collected and centrifuged at 400 g for 20 minutes and the resulting 
supernatant was passed through a 0.45 µm filter to remove cell debris. This sample was 
then concentrated with a 100k MWCO filter (Merck Millipore Ltd.), centrifuged at 110,000 
g for 2 hours, and the EV pellet was suspended in PBS and stored at 4oC until use (< 2 
weeks). EV size distributions and EV concentrations of HPNE and PANC-1 EV samples 
were analyzed using a NanoSight LM10 instrument and Nanoparticle Tracking Analysis 
Software (Malvern Instruments). Figure 7-8 reveal the results for purified PANC-1 and 
HPNE EVs samples isolated by ultracentrifugation demonstrating similar size distributions 
with similar mean diameters. 
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Figure 7. NanoSight analysis of PANC-1 EV size distribution profiles. Summarized results 
indicate the mean ± SEM of three replicate measurements. 
 
 
 
 
 
    
 
 
 
 
   
Figure 8. NanoSight analysis of PANC-1 EV size distribution profiles. Summarized results 
indicate the mean ± SEM of three replicate measurements. 
HPNE 
PANC-1 
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3.2.2. EV Free Serum Preparation 
 Serum from healthy human subjects (Valley Biomedical Products & Services, Inc.) was 
centrifuged at 135 g for 15 minutes to allow lipid flotation, after which isolated serum 
samples were centrifuged at 9391 g for 45 minutes to precipitate insoluble debris and allow 
flotation of remaining lipid. This serum sample was then centrifuged at 110,000 g for 3 
hours to precipitate EVs and the supernatant was collected and stored at -80oC as EV-free 
serum 
3.2.3. Fluorescent Lipophilic dye (DiO Dye)  
 Fluorescent lipophilic dyes are usually termed as membrane dyes. General membrane 
labeling with fluorescent lipophilic dyes has the advantages of being simple, rapid, and 
applicable for almost any type of cell. Since the EVs have a similar lipid membrane like 
the cells, these dyes can be used to label EVs as well.  In this study we used Vybrant DiO 
cell-labeling solution (Invitrogen), DiO (DiOC18 (3) or (3, 3′-dihexadecyloxacarbocyanine 
perchlorate)) also known as DiO dye for fluorescently labeling the EV membrane. The 
lipophilic carbocyanine dyes are known to be weakly fluorescent on water but are highly 
fluorescent, photostable and label membrane through lateral diffusion making them the 
right candidate for our study (Honig and Hume 1989).  DiO was utilized for this analysis 
since it requires a one-step labeling process, unlike other fluorescent lipophilic dyes that 
have been used to stain EVs. For example, PKH dyes require extended incubation in an 
iso-osmotic mannitol solution, which can reduce EV yields and increase the variability of 
downstream EV analyses (Kanwar, Dunlay et al. 2014). 
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3.2.3.1 Determining the blocking buffer 
One major issue with using the DiO dye was that this dye is mainly used to stain 
fixed cells or EVs for live cell imaging and EVs intake in cells. When using the dye in 96-
well black polystyrene plate had several unseen problems. 
The polystyrene plate being hydrophobic facilitates lipidic reactions causing the 
dye to bind to it resulting in a high background signal. The usual blocking buffer contains 
TWEEN-20 to get rid of these unbound hydrophobic regions. The buffer contains 5% BSA 
(Bovine serum albumin) in PBST (PBS +0.01% Tween 20) but it did not reduce the 
background signal.  
The aim was to focus on getting rid of these hydrophobic regions that is available 
for the dye to bind to. Triton X 100, is a nonionic surfactant that has an uncharged 
hydrophilic head group of  polyethylene oxide chain (on average it has 9.5 ethylene oxide 
units) and an aromatic hydrocarbon lipophilic or hydrophobic group tail, known to break 
lipid-lipid interactions rather than protein-protein interactions. This feature of Triton X can 
be exploited to get rid of the unbound hydrophobic region (Johnson 2013). We performed 
a study to test the blocking efficiency of three different blocking buffer followed with 
adding the DiO dye to a 96-well plate. The results revealed that blocking buffer with 
TritonX-100 showed low background signal in comparison to other blocking buffers 
(Figure 9). 
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Figure 9. The fluorescence readout for the DiO dye after using three different types of 
blocking buffer , where blocking buffer consists of 5% BSA in PBST, SuperBlock™ 
(ThermoFisher Scientific) is a commercially available buffer and blocking buffer +0.02% 
tritonX-100  
 
3.2.3.2. Determining Triton-X 100 concentration for wash step 
Apart from being used in the blocking step, triton X100 is good at getting rid of 
unspecific binding and lipid-lipid interaction. However, Triton X 100 being a detergent is 
used to lyse cells, and studies have shown how different concentration of triton X 100 can 
cause EV lysis (Osteikoetxea, Sodar et al. 2015). The next aim was determining the right 
concentration of TritonX-100 in the wash buffer to get rid of unspecific binding of the dye 
along with not having any effect on the bound EVs. Three wash step for 10 minutes is 
equivalent to a total of 30 minutes interaction of the EVs with the wash buffer. The 
following experiment studied the influence of 5 different concentration of TritonX-100 on 
EVs incubated for 1 h and the EV content was then measured using the NanoSight 
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instrument. The study revealed that 0.01% tritonX-100 works best for the EV without 
damaging the integrity of the EVs and having the highest yield of 90.85% (Figure 10). 
 
Figure 10.The influence of different concentrations of TrironX-100 on total EVs yield. 
 
To summarize, the following procedure was developed to label the EVs: 
1. High-binding 96-well black-walled, clear-bottom 96-well microplates (Corning 
3601) were incubated with 100 μL/well of a 1:500 dilution of anti-CD81 
(0.5mg/mL, BioLegend, Clone #5A6) antibody for 12 h at 4oC  
2. Wash twice with PBS Incubated with 200 μL/well of blocking (5% BSA in 0.02% 
TritonX-100, 0.05% Tween20 in PBS) buffer for 2 h at room temperature 
3.  Incubate the EVs for 12 h at 4oC Add the 2.5 μL/ml Vybrant DiO cell-labeling 
solution (Invitrogen) diluted in PBS (100 μL/well) for 10 mins  
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4. Three 10 min washes with wash buffer (0.01% TritonX-100 and 0.05% Tween20 
in PBS), and then read at 470 nm excitation on a fluorescence microplate reader to 
measure lipid labeling. 
3.3 Results and discussions 
 The aim of this approach was to understand the feasibility of this technique, we 
designed an experiment to test the correlation of the lipid signal to the total number of EVs 
in the assay. For its accurate use as a normalizer in our assay, we labeled different known 
concentration of number of EVs for HPNE and PANC-1 with the DiO dye and performed 
a correlation study of the labeling of DiO for HPNE vs PANC-1 EVs. 
A known concentration of EVs were first spiked into EV - free serum, followed 
with capture on the surface of a 96-well plate using a capture antibody, they were then 
labeled with the DiO, and the plate reader was used to measure the fluorescent signal at 
470nm emission. Figure 11, represents the fluorescence signal for same number of EVs 
labeled in HPNE and PANC-1 populations. We performed linear regression analysis with 
95% confidence intervals, which shows that PANC-1 EVs have a slope of 1.25 and R2 = 
0.88 and HPNE EVs have a slope of 1.099 with R2 = 0.92. This suggests that there is a 
linear relationship of the binding of the dye to the number of EVs in a sample, irrespective 
of its cellular origin.  
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Figure 11.  Standard curves of DiO-stained PANC-1 and HPNE EV standards. Data 
represent means ± SEM, n= 3 replicates/ sample 
 
To further validate the data, we performed a correlation between the signal values 
for HPNE and PANC-1 EVs , Figure 12, represents the data showing a  correlation with  
R2 = 0.97. This approach exhibited robust performance to differentiate sequential 2-fold 
EV dilutions, with all HPNE samples and all but the lowest PANC-1 samples significantly 
differing from the next dilution sample. Thus indicating that any potential differences in 
membrane composition or EV size distributions did not affect DiO staining. HPNE and 
PANC-1 EVs stained with DiO demonstrated similar fluorescent intensity on confocal 
microscope images, which was distinct from the signal of a quantum dot probe bound to 
these EVs (Figure 13) 
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Figure 12. Correlation of DiO signal from PANC-1 and HPNE EV standards. Data 
represent means ± SEM, n= 3 replicates/ sample 
 
 
Figure 13. Confocal images of PANC-1 and HPNE EVs labeled with DiO and an EpCAM-
specific quantum dot probe (Qdot 605-EpCAM). Scale bar = 25µm. 
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CHAPTER  
4 Measuring the expression of cancer specific exosomal surface markers 
4.1. Introduction 
The American Cancer Society estimates close to 55,440 new cases of pancreatic 
cancer will be diagnosed in the US in 2018, comprising 3% of the total number of new 
cancer cases (Cancer Facts and Figures, 2018, American Cancer Society). However, the 
estimated number of deaths from pancreatic cancer is 44,330 in 2018, about 7% of all 
cancer deaths. With a 5-year survival rate of close to 8.5%, pancreatic cancer is the fourth 
leading cause of cancer in both men and women. One of the main reasons for this is the 
inability for proper diagnosis, which in turn leads to its poor prognosis. 
The location of the pancreas in the body makes it difficult to see or feel early tumors 
(Cancer Facts and Figures, 2018, American Cancer Society). Majority of pancreatic 
cancers (PC) are known to progress to either locally advanced or metastatic disease before 
showing any symptoms, causing metastasis to be one of the most common causes of death 
in PC patients (Hidalgo 2010). Yachida et al. sequenced the genomes from seven pancreatic 
cancer metastatic samples to study the relationship between primary and metastatic cancer 
(Yachida, Jones et al. 2010). The novel insights from this study into the genetic information 
of pancreatic cancer progression revealed that it takes 5 years for the acquisition of 
metastatic ability after a parental tumor but the non-metastatic cell is detectable prior to 
this. This data established a broad time window of opportunity for early detection to 
prevent deaths from metastasis (Yachida, Jones et al. 2010, Herreros-Villanueva and 
Bujanda 2016) 
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Exocrine cancer is by far the most common type of pancreatic cancer, wherein 
about 95% of cancers are pancreatic adenocarcinoma (National Cancer Institute, 
Surveillance, Epidemiology and End Results Program, 2018). Pancreatic ductal 
adenocarcinomas (PDAC) are developed from three precursor lesions: pancreatic 
intraepithelial neoplasia (PanIN) lesions, intraductal mucinous neoplasm (IPMN) and 
mucinous cystic neoplasms (MCN) (Yachida, Jones et al. 2010). Diagnosis of PC is 
challenging due to the non-specific symptoms in patients which leads to late diagnosis. In 
fact,  sometimes pancreatic masses are indistinguishable from chronic pancreatitis or 
benign pancreatic cysts when a biopsy is obtained , furthermore, pathological results can 
often be inconclusive (Yachida, Jones et al. 2010). Currently, there are no reliable markers 
that can accurately diagnose, classify and predict the biological behavior of pancreatic 
tumors. Therefore, it is imperative to  focus on identifying and developing  biomarkers, 
with high specificity and sensitivity  that can help  detect initial lesions in the early stages 
of pancreatic cancer (Herreros-Villanueva and Bujanda 2016, Nuzhat, Kinhal et al. 2017) 
There are potential serum biomarkers for diagnosis, disease progression and 
monitoring of therapy (Hidalgo 2010). Carbohydrate antigen, CA19-9 is currently the most 
extensively studied biomarker and the only one approved by the FDA with demonstrated 
clinical usefulness (Goonetilleke and Siriwardena 2007). However, it has a major limitation 
of not being specific for pancreatic cancer with elevated levels in acute cholangitis, live 
cirrhosis, pancreatitis and obstructed jaundice (Loosen, Neumann et al. 2017). 
Furthermore, patients who are negative for Lewis antigen a or b, are unable to synthesize 
CA19-9 and have undetectable levels of serum CA19-9. CA19-9 levels are useful in 
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monitoring patients diagnosed with PC, but the use as a screening or diagnostic tool is still 
a concern (Hidalgo 2010, Loosen, Neumann et al. 2017) 
 4.2. EpCAM and EphA2 as pancreatic cancer specific markers 
To test the ability of this approach to quantify the mean expression of EV 
biomarkers, we employed quantum dots labeled with antibodies specific to different EV 
membrane biomarkers associated with pancreatic cancer to analyze EVs isolated from 
PANC-1 and HPNE cell lines. We focused on two cancer-specific markers– Ephrin type-
A receptor 2 (EphA2) and Epithelial cell adhesion molecule (EpCAM). 
Ephrin type-A receptor 2 (EpHA2) , originally named epithelial cell kinase (Eck) 
is a transmembrane receptor tyrosine kinase, normally expressed at low levels in adult 
epithelial tissues (Lindberg and Hunter 1990). EphA2 is also an oncoprotein, with roles in 
the regulation of cell growth, survival, angiogenesis, and migration, along with an ability 
to confer malignant potential to non-transformed epithelial cells (Zelinski, Zantek et al. 
2001). Studies have revealed that EphA2 is over-expressed in a number of human cancers, 
and increased levels of EphA2 are associated with aggressive disease and poor clinical 
outcomes (Duxbury, Ito et al. 2004, Mudali, Fu et al. 2006). In pancreatic cancers, EphA2 
is over-expressed in pancreatic adenocarcinoma cell lines with higher metastatic potential, 
while suppression of EphA2 expression appears to lessen the invasive phenotypes of the 
same cell lines. This information enables EphA2 biomarkers to be used not only as a 
diagnostic tool but also helps provide support for EphA2 targeted therapies in cancer 
(Duxbury, Ito et al. 2004, Duxbury, Ito et al. 2004). 
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Epithelia cell adhesion molecule (EpCAM) is a surface glycoprotein of 
approximately 40 kDa that can play a role in cell adhesion and tissue plasticity, along with 
regulating  cell proliferation and differentiation (Schnell, Cirulli et al. 2013). It is known 
to be expressed on a subset of normal epithelia and overexpressed in a variety of different 
tumors (Imrich, Hachmeister et al. 2012). EpCAM is a primary tumor marker, showing 
evidence of downregulation in circulating tumor cells during epithelial-to-mesenchymal 
transition (Duxbury, Ito et al. 2004, Duxbury, Ito et al. 2004, Visvader and Lindeman 
2009). Studies have shown that pancreatic cancer EVs exhibit certain markers related to 
the cancer initiating cells, which include Tspan8, MET and EpCAM (Nuzhat, Kinhal et al. 
2017). Several other studies unfolded higher expression levels of EpCAM that 
corresponded to poor prognosis in ovarian, breast and pancreatic cancer (Schnell, Cirulli 
et al. 2013). 
4.3 Materials and methods  
 To validate the expression levels of these markers in HPNE and PANC-1 EVs we 
performed western blot analysis and ELISA using the same number of EVs for both cell 
types. 
4.3.1 Western blot  
 Western blots (SDS-PAGE) were performed with 5 μg/sample HPNE and PANC-1 
cells protein lysate as measured by Pierce™ BCA Protein Assay Kit (ThermoFisher 
Scientific) and same number of HPNE and PANC-1 EVs. The gel was transferred to the 
membrane using BioRad Trans-Blot Turbo. The membranes were blocked using 5% 
BSA/PBST blocking solution, and 1:1000 dilutions of the indicated primary antibodies 
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anti-human-EphA2 (Sigma-Aldrich , clone D7), anti-human EpCAM (ThermoFisher 
Scientific, clone #VU-1D9), anti-human TSG101 (Abcam, 4A10) and anti-human GM130 
(Santa Cruz Biotechnology, B-10) and a 1:5000 dilution of HRP-labeled secondary 
antibody (goat anti-mouse, IgG H&L, Abcam, ab6789) in 5% BSA/PBST, with Clarity™ 
Western ECL substrate (Bio-Rad), and acquiring chemiluminescent images. 
4.3.2. EV ELISA Assay 
 Reduced surface area 96-well microtiter plates (Corning 3690) were incubated with 
50 µL/well of a 1:500 dilution of anti-human CD81 (0.5 mg/mL, BioLegend, Clone 
#5A6) in PBS for 12 h at 4oC.  
 Plates were then washed twice with PBS for 5 min per wash, incubated with 5% 
BSA in PBS with 0.05% Tween-20 (PBST) for 2 h at room temperature (50 
µL/well), then washed four times with PBST at a minimum of 5 min per wash.  
 EV samples (25 µL/well) were added to the plate, which was then incubated 
overnight at 4oC and then washed four times with PBST.  
 The captured EVs were then incubated with biotin-labeled anti-human EpCAM 
(1μg/mL, ThermoFisher Scientific, clone #VU-1D9) and anti-human EphA2 biotin 
(1 μg/mL, R&D Systems) in 5% BSA/PBST for 1 h at 37ºC (50 µL/well), washed 
four times with PBST, and 
 Then incubate with a 1:3000 dilution of HRP-conjugated streptavidin (1.25mg/mL, 
ThermoScientific Pierce) in 5% BSA/PBST for 1 h at room temperature (50 
µL/well).  
 Sample wells were then washed four times with PBST, incubated with 50 µL/well 
TMB reagent (ThermoScientific, Inc.) for 10-15 min at room temperature then 
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supplemented with 50 µL/well stop solution (2 M H2SO4) and read for absorbance 
at 450 nm on a microplate reader. 
4.3.3. Statistical Analyses 
 GraphPad Prism version 8.0.2 (GraphPad Software) was used for all calculations. 
Statistical analyses were performed using Student’s t-tests, one-way ANOVA with 
Tukey’s multiple comparison test as determined by sample distribution and variance. 
Differences with p-values < 0.05 were considered statistically significant. Figures were 
prepared using GraphPad Prism 8.0.2 (GraphPad Software). All data points are derived 
from three biological or technical replicates as indicated for each experiment. 
4.4 Results and discussions 
 Western blot analysis of cell lysates generated from HPNE and PANC-1 cells revealed 
that EphA2 and EpCAM expression were enhanced in PANC-1 versus HPNE cells, and 
further increased in equal numbers of EVs isolated from PANC-1 versus HPNE cells, 
stating that these two markers could further be used as targets for distinguishing normal vs 
cancer derived EVs (Figure 14) Cell lysate expression of the endosomal sorting complex 
required for transport (ESCRT) protein TSG101, an endosome-associated marker (Raiborg 
and Stenmark 2009, Willms, Johansson et al. 2016), was similarly expressed in both cell 
lysates but was less abundant in HPNE versus PANC-1 EVs, although the reason for this 
difference is not clear. Neither EV population appreciably expressed the Golgi marker 
GM130, which is not found in EV populations (Keerthikumar, Gangoda et al. 2015). 
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Figure 14. EphA2 and EpCAM are selectively expressed on PANC-1 vs. HPNE EVs. 
Western blot analysis of protein expression in equal numbers of PANC-1 and HPNE EVs 
and cell lysate. TSG101 as a positive marker for EVs and GM130 as a negative marker for 
EVs. 
 
We then used the gold standard to quantify the expression of these markers on 
HPNE and PANC1 EVs. Similar EpCAM and EphA2 expression differences were also 
observed in EV ELISAs in which equivalent numbers of purified EVs isolated from these 
cell lines were captured with anti-CD81 antibody, a general EV marker (Kowal, Arras et 
al. 2016),    and probed with EpCAM or EphA2 detection antibodies. The slopes of all 
these dilution curves were significantly different from zero, although ELISA signal from 
these two EV populations did not exhibit parallel increases with increasing EV numbers in 
the EphA2 EV ELISA, indicating an apparent weak detection efficiency for EphA2 
expression on the HPNE-derived EVs.  
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Figure 15, linear regression analysis found that EpCAM signal demonstrated 
similar increases with increasing EV number (3×107 ~ 5×108 EVs) in EVs derived from 
both PANC-1 (p<0.0001, R2= 0.91) and HPNE (p = 0.0134, R2 = 0.96) cell cultures. In 
EphA2 signal also demonstrated trends to increase with increasing numbers of EVs from 
PANC-1 (p <0.0001, R2 = 0.85), albeit with greater signal variability than observed in the 
EpCAM EV ELISA, but no significant trend to increase was observed in the HPNE 
samples (p=0.4489) (Figure 16) However, ELISA signal for both assays demonstrated poor 
sensitivity to discriminate differences in total EV expression of these biomarkers in 
sequential EV dilutions (Table.1-2), being unable to differentiate signal arising from 2-fold 
dilutions of most of these EV samples. Based on these results we selected EphA2 and 
EpCAM as our two candidate markers for detection and distinguishing of pancreatic cancer 
derived EVs from normal EVs. 
     
Figure 15. EpCAM signal from EV ELISAs of PANC-1 and HPNE EV concentration 
standards captured with anti-CD81 antibody. Data represent means ± SEM, n= 3 
replicates/sample. 
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Figure 16. EphA2 signal from EV ELISAs of PANC-1 and HPNE EV concentration 
standards captured with anti-CD81 antibody. Data represent means ± SEM, n= 3 
replicates/sample. 
 
 
Table 1. Student’s t-test analysis of EVs ELISA-measured for EpCAM expression from 
equal number of HPNE and PANC-1 EVs. 
 
 
Table 2. Student’s t-test analysis of EVs in ELISA-measured for EphA2 expression from 
equal number of HPNE and PANC-1 EVs. 
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CHAPTER  
5 NORMALIZED DETECTION OF TARGET EV MARKERS USING THE 
QUANTUM DOT ASSAY (QDOT ASSAY) 
5.1 Quantum dots (Qdot) as detection probes 
The assay uses quantum dots as the fluorescent detection probes, which are 
semiconductor nanoparticles having physical and optical properties making them the useful 
for high-resolution labeling and imaging (Pathak, Davidson et al. 2007). In addition to 
having high quantum yield and high extinction coefficient which makes them brighter and 
more photostable than other fluorescent probes, they have narrow emission spectral peak 
which prevents spectral overlap mostly seen with other organic fluorophores which plays 
to the advantage of using them for multiplexing (Pathak, Davidson et al. 2007, Toseland 
2013). Quantum dots have a broad excitation spectrum, suggesting that the same excitation 
wavelength could be used to excite two or more dots. We selected two quantum dots with 
emission spectra maxima at 605 nm (QD605) and 655 nm (QD655) as the two fluorescent 
probes for our assay. We ran a preliminary test using a mixture of the same concentration 
of the quantum dots and excited them at 390nm to measure the signal intensities at 605 and 
655 at the same time. Figure 17, shows that the signal intensities were very similar for both 
the qdots, implying that we could further use them together in our assay.  
5.2 Materials and methods 
 To test the difference of between normalized and not normalized signals for 
EpCAM and EphA2, we designed the Qdot assay to measure the total signal from the DiO 
dye, followed with measuring the signal from quantum dot conjugated antibodies, anti-
EpCAM-QD605 and anti-EphA2-QD655 
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Figure 17. Replicate emission spectra of equal mixtures of QD605 and QD655 particles 
analyzed at two different concentrations (390 nm excitation).   
 
Day 1: 
 High-binding 96-well black-walled, clear-bottom 96-well microplates (Corning 
3601) were incubated with 100 μL/well of a 1:500 dilution of anti-CD81 
(0.5mg/mL, BioLegend, Clone #5A6) antibody for 12 h at 4oC, then washed twice 
with PBS 
Day 2: 
 Then incubated with 200 μL/well of 5% BSA/PBST in 0.02% TritonX-100 for 2 h 
at room temperature, 
  Then aspirated and incubated with 50 µL/well of EV for 12 h at 4oC.  
Day 3: 
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 Sample wells were then washed with PBS for 5 min, incubated for 10 min at 37oC 
with a 2.5 μL/mL Vybrant DiO cell-labeling solution (Invitrogen) diluted in PBS 
(100 μL/well), subjected to three 10 min washes with 0.01% TritonX-100 in PBS, 
and then read at 470 nm excitation on a fluorescence microplate reader to measure 
lipid labeling. 
 Biotin-labeled anti- EphA2 (0.5mg/mL, R&D system) antibodies were diluted 
1:200 in 5% BSA/PBST and added to sample wells (50 μL/well) and incubated for 
1 h at 37oC, then washed three times for 5 min with PBST 
 Add 12nM of streptavidin-coated Qdot 655 sample wells (50 μL/well) and 
incubated for 1 h at 37oC shaking at 100 rpm, then washed three times for 5 min 
with PBST 
 Block the excess streptavidin regions of the Qdot 655 with biotin (Biotin blocking 
kit, ThermoFisher Scientific) and incubate covered for 10 mins at 37°C shaking at 
100 rpm (50 μL/well). then washed three times for 5 min with PBST 
 Biotin-labeled anti-EpCAM (0.5mg/mL; ThermoFisher Scientific, clone #VU-
1D9) antibodies were diluted 1:200 in 5% BSA/PBST and added to sample wells 
(50 μL/well) and incubated for 1 h at 37oC, then washed three times for 5 min with 
PBST 
 Add 12nM of streptavidin-coated Qdot 605 (Invitrogen) sample wells (50 μL/well) 
and incubated for 1 h at 37oC shaking at 100 rpm, then washed three times for 5 
min with PBST 
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 incubated for 1 h at 37oC, washed three times for 10 min with PBST, and read in a 
fluorescence microplate reader (390 nm excitation) to quantify DiO (500 nm) and 
quantum dot (605nm and 665 nm) signal intensity. 
5.3 Results and discussions 
5.3.1 Total signal for EpCAM-QD605 and EphA2-QD655 
 Analysis of EV- free serum spiked with serial dilutions of purified PANC-1 and 
HPNE EVs revealed progressive signal increases after CD81-captured EVs were 
hybridized with anti-EpCAM-QD605 and anti-EphA2-QD655, in correspondence with 
input EV concentrations (Figures 18-19). The Qdot assay is designed to first quantitate 
the number of EVs in the sample in using the DiO signal, followed with measuring the 
signals at 605nm and 655nm with 390nm excitation. We summarized the standard curves 
for EpCAM total expression levels on the same number of EV samples revealing a 
linearity for both HPNE and PANC-1 EVs (Figure 20). The EpCAM expression on HPNE 
EVs revealed a slope of 5.28 × 10-7, and for PANC-1 EVs a slope of 4.722 × 10-7 relative 
fluorescent units (RFU) per input EV, respectively, with robust correlation coefficients 
(R2 = 0.99 and 0.90). In, the expression for EphA2 on HPNE EVs revealed a slope of 5.14 
× 10-7, and for PANC-1 EVs a slope of 4.69 × 10-7 , relative fluorescent units (RFU) per 
input EV , respectively, with robust correlation coefficients (R2 = 0.98 and 0.89) (Figure 
21). Furthermore, student’s t-test analysis on the expressions for EpCAM and EphA2 in 
PANC-1 vs HPNE EVs demonstrated good ability to discriminate between differences in 
the expression of these EV biomarkers.  
 
                                                                                                                      
 
61 
              
Figure 18. Fluorescence spectra of QD605-EpCAM and QD655-EphA2 on CD81-captured 
PANC-1 EVs. 
 
 
            
Figure 19. Fluorescence spectra of QD605-EpCAM and QD655-EphA2 on CD81-captured 
HPNE EVs. 
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Figure 20. Standard curve for EpCAM expression on HPNE and PANC-1 EVs. Data 
represents means ± SEM, n=3 replicates/sample 
  
 
 
Figure 21. Standard curve for EpCAM expression on HPNE and PANC-1 EVs. Data 
represents means ± SEM, n=3 replicates/sample 
 
In Table.3, a significant difference was observed in the expression of EpCAM for the 
same number of EVs with p= 0.001 for 1.25 × 108 (lower sample size) EVs to p=0.01 for 
2 × 109 (higher sample size) EVs. Similarly, in Table.4, we observed a significant 
difference in the expression of EphA2 for the same number of EVs with p= 0.01 for 1.25 
× 108 (lower sample size) EVs to p=0.03 for 2 × 109 (higher sample size). These results 
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thus hold promise for the ability of this approach to detect similar differences in peripheral 
blood samples of cancer patients, which contain approximately 1011 EVs per mL (Kanwar, 
Dunlay et al. 2014) 
 
 
Table 3. Student’s t-test analysis of Quantum dot-measured EV EpCAM expression from 
equal numbers of HPNE and PANC-1 EVs. 
 
 
Table 4. Student’s t-test analysis of Quantum dot-measured EV EphA2 expression from 
equal numbers of HPNE and PANC-1 EVs. 
 
5.3.2 Normalized signal for EpCAM and EphA2 
Notably, this assay was performed using known amounts of EVs spiked in EV free 
serum, but only highly purified EV samples can be accurately quantified using current 
methods. We propose that staining with a lipophilic fluorescent dye can be used to assess 
the relative lipid content of affinity-captured EVs to quantify their abundance and 
normalize the mean expression of EV biomarkers.  
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DiO signal did not differ between equal numbers of HPNE and PANC-1 EVs at 
any point in these concentration curves (Figure 22) These HPNE and PANC-1 EVs 
dilutions were then analyzed to determine if their EpCAM-QD605 and EphA2-QD655 
signals differed after they were normalized against their DiO signal to correct for differing 
EV concentrations. 
       
 
Figure 22. DiO signal from serial dilution samples of PANC-1 and HPNE EVs. Data 
represents means ± SEM, n=3 replicates/sample 
 
The DiO signal for number of EVs and the Quantum dot signal for the two markers, 
was used with a simple formula to measure per EV expression levels, where expression 
of the biomarker per EV  = (Signal intensity of the Qdot / Signal intensity of the DiO). 
The results will reveal the information of the markers on each EV type, implying that the 
values from the test show a trend with no significant deviation from zero and no significant 
difference in the data points for different number of EVs within each population. In, we 
find that biomarker signal, both EpCAM and EphA2 did not significantly vary with input 
EV number and that the slope of these signals among these samples did not significantly 
differ from zero (Figures 23-24). These results strongly imply that DiO signal accurately 
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reflects increasing EV abundance, as previously indicated (Figure 11), and is sufficient to 
correct for differences in EV number to normalize EV biomarker signals to EV number, 
eliminating the need for EV purification and NTA quantification, which can introduce 
variation and require significant amounts of starting sample. 
    
 
Figure 23. DiO-normalized EpCAM-Qdot 605 signal detected using HPNE and PANC-1 
EV concentration standards. Data represents means ± SEM, n=3 replicates/sample 
 
     
 
Figure 24. DiO-normalized EphA2-Qdot 655 signal detected using HPNE and PANC-1 
EVs concentration standards. Data represents means ± SEM, n=3 replicates/sample 
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CHAPTER  
6 CLINICAL VALIDATION OF THE QDOT ASSAY ON TWO DIFFERENT 
PANCREATIC CANCER COHORT 
6.1 Clinical cohort information 
To test the utility of this approach in clinical samples, we investigated two different 
cohorts one from obtained from subjects enrolled at the Baylor University Medical Center 
(n=74), the Baylor cohort and the other patients with pancreatic cancer and non-cancer 
controls enrolled at Weill Cornell Medicine College, the Cornell cohort.  We tested whether 
this assay approach could distinguish pancreatic cancer patients from non-malignant 
control patients. In this study, we analyzed DiO-normalized anti-EpCAM-QD605 and anti-
EphA2-QD655 probe signal on CD81-captured EVs from plasma and serum samples 
drawn from a cohort of 74 subjects (Table 5) and 32 subjects (Table 6) respectively.  The 
Baylor cohort included healthy non-malignant control subjects, and pancreatic cancer 
patients with stage I/II, III, or IV tumors (11 – 21 subjects/group) while the Cornell cohort 
included 20 pancreatic cancer patients and 12 non-malignant controls (e.g. liver injury, 
pancreatitis and cholangitis). 
6.2 Materials and methods 
6.2.1 Baylor Cohort clinical samples 
Pancreatic cancer and healthy control patient plasma samples were obtained from 
subjects enrolled at the Baylor University Medical Center. Written informed consent was 
obtained from all patients prior to participating in the study and the study was approved by 
the Institutional Review Board at Baylor Scott & White Health (IRB # 015-196). 
Demographic information including sex, age, and cancer stage is recorded in Table 5. 
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Samples were added to the quantum dot assay in a randomized order, but investigators 
were not blind to the group identity of the samples during data processing or analysis. 
 
Table 5. Demographic information of pancreatic cancer cohort (N= 21, Control; N=53, 
Cancer) 
 
Table 6. Demographic information of the pancreatic cancer cohort, which contains 12 non-
cancer controls and 20 patients with pancreatic cancer. 
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6.2.2 Cornell cohort clinical samples 
Serum samples were obtained from patients with pancreatic cancer and non-cancer 
controls enrolled at Weill Cornell Medicine College in accordance with a protocol 
approved by its Institutional Review Board. Demographic information including sex, age, 
and CA19-9 level is recorded in Table 6. Samples were added to the quantum dot assay in 
a randomized order, but investigators were not blind to the group identity of the samples 
during data processing or analysis. 
6.2.3 Statistical Analysis  
GraphPad Prism version 8.0.2 (GraphPad Software) was used for all calculations. 
Statistical analyses were performed using Student’s t-tests, one-way ANOVA with 
Tukey’s multiple comparison test as determined by sample distribution and variance. 
Differences with p-values < 0.05 were considered statistically significant. We wrote a 
MATLAB program to generate a logistic regression model to fit the clinical samples data 
and generate probabilities, which was then used to generate the ROC curves. Figures were 
prepared using GraphPad Prism 8.0.2 (GraphPad Software). All data points are derived 
from three biological or technical replicates as indicated for each experiment. 
6.3 Results and discussions 
6.3.1 Baylor Cohort clinical validation 
We directly added plasma samples from this cohort to a black 96-well plate coated 
with anti-CD81 antibody to allow EVs capture, then stained with DiO, hybridized with 
anti-EpCAM-QD605 and anti-EphA2-QD655, and analyzed on a fluorescent plate reader 
to quantify the fluorescent signal arising from their lipid labeled EVs and biomarker 
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expression. No difference in total EV-associated EpCAM or EphA2 expression was 
detected between the cancer and healthy, non-malignant groups in this cohort (Figure 25 
A-B), however, there was a significant difference in the DiO signal for the cancer vs 
healthy, non-malignant control (p = 0.0021) (Figure 26). 
On further evaluating the clinical information provided for the samples, we noticed 
that there was no mention if the healthy subjects had any underlying diseases which can 
play a role in the amount of EVs released and observed for the healthy controls. Another 
factor contributing to this could be patient to patient variability, for example a particular 
known value of EVs in a healthy normal patient could be an increased level in a cancer 
subjects. Hence we cannot use the number of EVs as a stand-alone diagnostic marker for 
cancer (Xu, Rai et al. 2018). 
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Figure 25. Raw (A) EpCAM and (B) EphA2 expression on CD81-captured plasma EVs 
from plasma samples of patients with pancreatic cancer (N=53) and their healthy, non-
malignant controls (N=21).  Data represent means ± SEM (ns = not significant by Student’s 
t-test), n= 2 replicates/sample. 
 
Figure 26. DiO signal from plasma samples drawn from patients with pancreatic cancer 
and those without cancer. (**p < 0.01 by Student’s t-test), Data represent means ± SEM, 
n= 2 replicates/sample. 
(A) 
(B) 
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The assay quantum dot signals (Figure 25 A-B) was then normalized to the EV DiO 
signal (Figure 26), which revealed both EpCAM and EphA2 expression levels for 
pancreatic cancer vs control (Figure 27 A-B). On comparing the expression of EpCAM 
and EphA2 for control to cancer patient we see a significant difference with p-value 0.001 
and p-value 0.04 respectively, affirming that per EV protein expression levels for these two 
biomarkers could help distinguish control and cancer subjects. 
 
Figure 27. DiO-normalized (A) EpCAM and (B) EphA2 expression on CD81-captured 
plasma EVs from plasma samples of patients with pancreatic cancer (N=53) and their 
healthy, non-malignant controls (N=21).  Data represent means ± SEM (*p<0.05, and 
**p<0.01 by Student’s t-test), n= 2 replicates/sample. 
 
(A) 
(B) 
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The receiver operating characteristic (ROC) analyses were performed to evaluate 
the ability of raw and DiO-normalized signal from these EV biomarkers to differentiate 
patients with and without pancreatic cancer. No difference was detected for area under the 
curve (AUC) values for raw (0.59) and DiO-normalized (0.61) EphA2 EV signals (Figure  
28B), but found an AUC difference between the normalized (0.75) and raw (0.60) EpCAM 
EV signals (Figure 28A) that were not improved by combined analysis of both EV 
biomarkers (Figure 29). Here, the combined markers did not improve the ability to 
differentiate the cancer from the normal subjects, mainly due to the ability of EphA2 
markers for this particular cohort. 
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Figure 28. ROC curves of the ability of raw and DiO-normalized (A) EpCAM signal or (B) 
EphA2 signal to differentiate pancreatic cancer patients from their healthy controls. 
Researchers performing these analyses were not blinded to sample identity. 
 
(A) 
(B) 
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Figure 29. ROC curves of the ability of raw and DiO-normalized data for combined 
EpCAM and EphA2 signal to differentiate pancreatic cancer patients from their healthy 
controls. Researchers performing these analyses were not blinded to sample identity 
 
On further analyzing the data (Figure 28B), we can see that the signal did not show 
a great improvement for raw vs normalized data. One of the reason could be the samples 
for this cohort, as previously mentioned EphA2 is more of a metastatic marker, and as we 
did not have any additional clinical information regarding the metastatic status of the 
cancer patients we could not further analyze the data from the assay to patient history. We 
performed subgroup analysis by cancer stage that revealed the DiO-normalized EpCAM 
signal, but not EphA2 signal, significantly differed between patients with stage III or stage 
IV cancer and non-malignant controls (Figures 30-31). 
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Figure 30. DiO-normalized EpCAM expression on CD81-captured EVs captured from 
plasma samples of patients with stage I+II (N=11), stage III (N=21), and stage IV (N=21) 
pancreatic cancer and their healthy, non-malignant controls (N=21). Data represent means 
± SEM. (“ns” denotes that the indicated comparisons are not significant when analyzed by 
1-way ANOVA with Tukey’s post-test) 
 
 
Figure 31. DiO-normalized EphA2 expression on CD81-captured EVs captured from 
plasma samples of patients with stage I+II (N=11), stage III (N=21), and stage IV (N=21) 
pancreatic cancer and their healthy, non-malignant controls (N=21). Data represent means 
± SEM. (“ns” denotes that the indicated comparisons are not significant when analyzed by 
1-way ANOVA with Tukey’s post-test) 
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6.3.2 Cornell cohort 
In this study, we analyzed DiO-normalized anti-EpCAM-QD605 and anti-EphA2-
QD655 probe signal on CD81-captured EVs from serum samples drawn from a cohort of 
32 subjects (Table 6) that included non-cancer control subjects having other disease 
conditions like liver injury, pancreatitis and cholangitis (n=12) and pancreatic cancer 
patients (n=20). We directly added serum samples from this cohort to a black 96-well plate 
coated with anti-CD81 antibody to allow EV capture, then stained with DiO, hybridized 
with anti-EpCAM-QD605 and anti-EphA2-QD655, and analyzed on a fluorescent plate 
reader to quantify the fluorescent signal arising from their EV lipid and biomarker 
expression. There was a significant difference observed in total EV-associated EpCAM 
(p=0.02) and total EV associated EphA2 (p=0.01) levels between cancer and, non-cancer 
groups in this cohort (Figure 32A-B), but no significant difference observed in the DiO 
signal for the cancer vs non cancer groups (Figure 33).  
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Figure 32. Raw (A) EpCAM and (B) EphA2 expression on CD81-captured serum EVs 
from serum samples of patients with pancreatic cancer (N=20) and their non-malignant 
controls (N=12).  Data represent means ± SEM, n=3 replicates/sample (*p<0.05 by 
Student’s t-test) 
 
However, DiO normalization markedly reduced the biomarker overlap between 
these groups and increased the statistical significance of their detected EpCAM (p=0.0002) 
and EphA2 (p<0.0001) differences (Figure 34A-B). Receiver operating characteristic 
(ROC) analyses were performed to evaluate the ability of raw and DiO-normalized signal 
from these EV biomarkers to differentiate patients with and without pancreatic cancer 
(A) 
(B) 
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along with CA19-9 levels which is currently the most extensively studied biomarker and 
the only one approved by the FDA.  
 
Figure 33. DiO signal from serum samples drawn from patients with pancreatic cancer and 
those without cancer. (ns = not significant, p >0.05 by Student’s t-test), Data represent 
means ± SEM, n= 3 replicates/sample. 
 
The ROC analyses revealed the ability of raw and DiO-normalized EV biomarker 
signal to differentiate patients with and without pancreatic cancer found that the area under 
the curve (AUC) values to distinguish these groups were markedly improved when using 
normalized versus raw EpCAM (AUC of 0.92 versus 0.72) and EphA2 (AUC of 0.93 
versus 0.75) EV signals (Figure 35A-B). Serum levels of CA19-9, the only biomarker 
approved by the FDA for pancreatic cancer evaluations, exhibited an AUC of 0.74 in this 
cohort (Goonetilleke and Siriwardena 2007). 
 
 
 
                                                                                                                      
 
79 
 
Figure 34. EpCAM and EphA2 expression on EVs captured from patient serum samples. 
DiO-normalized (A) EpCAM and (B) EphA2 expression on CD81-captured serum EVs 
from serum samples of patients with pancreatic cancer (N=20) and their non-malignant 
controls (N=12).  Data represent means ± SEM, n=3 replicates/sample (*** p<0.001 and 
**** p<0.0001 by Student’s t-test) 
 
 
 
(A) 
(B) 
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Figure 35. ROC curves of the ability of CA19-9 level, and raw and DiO-normalized (A) 
EpCAM signal and (B) EphA2 signal to differentiate pancreatic cancer patients from their 
nonmalignant controls. Researchers performing these analyses were not blinded to sample 
identity. 
 
Combined ROC analyses performed with either unadjusted or DiO-normalized 
EpCAM and EphA2 data (Figure 36) produced AUCs greater than those detected with each 
marker alone (AUCs of 0.77 and 0.95, respectively) but these values could not conclusively 
determine if these combined analyses improved the ability to distinguish these groups due 
to the limitations imposed by the cohort size (n=32). However, future studies performed 
using larger cohorts could exploit the multiplex ability of this assay for improved diagnosis. 
(A) 
(B) 
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Serum levels of CA19-9, the only biomarker approved by the FDA for pancreatic cancer 
evaluations, exhibited an AUC of 0.74 in this cohort (Goonetilleke and Siriwardena 2007).  
 
 
 
Figure 36. Combined ROC curves indicating the ability of unadjusted and DiO-normalized 
EpCAM and EphA2 signal to differentiate pancreatic cancer patients from their 
nonmalignant controls. Researchers performing these analyses were not blinded to sample 
identity 
 
Based on the clinical information provided for these cancer controls, we performed 
subgroup analysis by cancer stage/ status that revealed the DiO-normalized EpCAM signal 
and EphA2 signal, significantly differed between patients with stage I+II and or metastatic 
cancer and non-malignant controls (Figure 37 and 38). However, these values could not 
conclusively determine if these markers could be used for early detection of pancreatic 
cancer and furthermore help in distinguishing non-malignant controls from metastatic 
cancer due to the limitations imposed by the cohort size. However, future studies performed 
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using larger cohorts could exploit the capabilities of these individual markers in 
distinguishing sub groups of cancers from their controls for improved diagnosis. 
 
Figure 37. DiO-normalized EpCAM expression on CD81-captured EVs captured from 
serum samples of patients with stage I+II (N=3) and metastatic (N=5) pancreatic cancer 
and non-malignant controls (N=12). Data represent means ± SEM, n=3 replicates/sample 
(**p<0.01 by Student’s t-test) 
 
 
Figure 38. DiO-normalized EphA2 expression on CD81-captured EVs captured from 
serum samples of patients with stage I+II (N=3) and metastatic (N=5) pancreatic cancer 
and non-malignant controls (N=12). Data represent means ± SEM, n=3 replicates/sample 
(**p<0.01 and *** p<0.001 by Student’s t-test) 
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CHAPTER  
7 CONCLUSIONS AND FUTURE WORK 
7.1. Summary and Conclusion  
 
This proof-of-principle data strongly implies that DiO-normalization to correct for 
differences in EV abundance may provide additional value to EV biomarker analyses. 
Quantum dot probes are a key component of this approach, since they are brighter, more 
photostable, and exhibit narrower emission peaks than most other fluorescent probes 
(Toseland 2013). These features are critical in visualizing biomarkers present on the limited 
surface area on an EV and to permit multiplex analyses with minimal signal interference. 
Standard approaches to correct for differences in EV abundance require normalization 
against an EV-associated factor or direct quantitation of isolated EVs, both of which are 
subject to significant variation. The proposed method provides a direct measure of 1) the 
relative EV abundance in a sample, without requiring a time-consuming and variable EV 
isolation step, 2) the total expression level of one or more EV biomarker targets, 3) and the 
average expression of such targets in the captured EV population. This allows one to 
distinguish between biomarker differences arising from changes in EV abundance or 
relative biomarker expression, which may reflect different regulatory processes. This can 
have important implications for certain disease conditions, including cancer, as these 
processes may require different interventions to address. The potential to simultaneously 
monitor these different parameters should improve the monitoring of tumor changes during 
cancer progression and in response to therapy (Lee, Fraser et al. 2018).  
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One limitation of this approach, however, is that altered abundance of other EVs 
other than the EV population of interest can influence the normalization process when 
analyses are performed on the total EV population. This is of concern for mixed EV 
populations present in clinical samples, and this approach therefore works best when the 
target EV population can be selectively captured using antibodies specific to a biomarker 
specific to the disease or tissue of interest. However, it appears that EV biomarker 
normalization can still improve the diagnostic performance of certain EV biomarkers even 
in mixed EV populations, as indicated in our proof-of-concept study. 
This approach utilizes a streamlined procedure and equipment found in most well-
equipped clinical laboratories, reducing one potential barrier for its clinical translation. It 
also allows multiple EV biomarkers to be analyzed in a single sample, and for the 
specificity of the assay to be readily modified to analyze different EV biomarkers 
associated with other disease conditions, including infectious diseases. The proof-of-
principle clinical sample analysis conducted for this study analyzed two biomarkers whose 
expression in EVs is of mounting interest (Klein-Scory, Tehrani et al. 2014, Yang, Im et 
al. 2017). Altered EpCAM expression is associated with primary tumors and appears to 
play a critical role in tumor growth and progression (Visvader and Lindeman 2009) while 
altered EphA2 expression is reported to be associated with tumor metastasis (Duxbury, Ito 
et al. 2004). Both biomarkers were enriched on EVs isolated from PANC-1 metastatic 
pancreatic carcinoma cells versus those isolated from HPNE nonmalignant pancreatic 
tissue cells, and on EVs present in the serum of patients with pancreatic cancer versus their 
non-malignant controls. Normalization of their EV expression to EV-related DiO signal in 
these samples markedly reduced the variability of these EV biomarkers in the 
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nonmalignant controls, decreasing their overlap with the pancreatic cancer patients to 
greatly improve their ability to distinguish these populations. A ROC analysis performed 
with both markers, however, was not able to conclusively demonstrate additional 
diagnostic benefit, despite a potential AUC increase, due to the limited cohort size. Further 
studies with larger well-defined cohorts are needed to determine if changes in the EV 
expression of these factors, alone or in combination, can distinguish pancreatic cancer 
patients with or without metastatic disease or at different cancer stages.  
7.2. Future work  
7.2.1. EVs as diagnostic markers in infectious disease 
  EV expression of pathogen-derived factors and changes in the EV abundance of 
specific host-derived factors can serve as diagnostic biomarkers, indicators of disease 
progression, and/or capture targets for the enrichment of pathogen-derived EVs for further 
analysis. Changes in EV composition during disease progression make them excellent 
biomarker candidates. The first blood-based EV test for cancer diagnosis became 
commercially available in the US in January 2016, marking a major step in the maturation 
of EVs as diagnostic factors (Sheridan 2016). The study of EVs for diagnosis of infectious 
disease is relatively new but shows great promise, particularly for intracellular bacterial 
pathogens, such as mycobacteria. Diagnosis of these pathogens normally requires culture 
or molecular analysis of pathogen samples derived from the site of infection and can 
misdiagnose patients with low pathogen loads. EVs containing pathogen-derived factors 
are actively secreted from most cells to accumulate in the circulation; some studies indicate 
that infection increases EV release rates (Singh, Smith et al. 2012, Hu, Gong et al. 2013) 
although it is not clear if this increase is common to all infections. Most current approaches 
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that diagnose active tuberculosis cases use sputum samples as the primary diagnostic 
specimen. However, there are limitations associated with sputum diagnostics and the 
World Health Organization has issued a call for new approaches that can diagnose active 
tuberculosis cases using minimally invasive patient samples, such as peripheral blood 
samples (Ferhan, Jackman et al. 2017).  
 Several studies have now indicated the potential of EVs from minimally or non-
invasive biological samples to detect such infections. Serum EV concentrations in mice 
infected with M. bovis BCG correlated and exhibited similar kinetics with M. bovis BCG 
mycobacterial load, suggesting the potential utility of serum EVs as diagnostic biomarkers 
for disease burden (Singh, Smith et al. 2012). A subsequent study used liquid-
chromatography and tandem mass spectrometry to identify 41 mycobacterial proteins in 
EVs derived from Mtb-infected J774 cells (Giri, Kruh et al. 2010) and in 2014, analysis of 
serum EVs isolated from patients with active tuberculosis cases detected numerous 
mycobacterial proteins, indicating that Mtb-derived EVs can function as markers of active 
disease (Kruh-Garcia, Wolfe et al. 2014). Mycobacterial RNA was also detected in EVs 
derived from Mtb-infected macrophages (Singh, Li et al. 2015), implying the potential for 
analyzing Mtb RNA in EVs as a diagnostic marker for active tuberculosis cases.  
 Nanoparticles are too small for direct detection by conventional flow cytometry, but 
one company has developed a high-resolution flow cytometer that can directly detect EVs. 
This specialized machine requires high-power lasers and high-performance 
photomultiplier tubes, detection of light scattering at customized angles, and the 
application of fluorescence-based thresholding to distinguish particles of interest from 
noise (Aras, Shet et al. 2004, van der Vlist, Nolte-'t Hoen et al. 2012). Standard flow 
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cytometers can, however, analyze multiplex bead-based platforms to detect and analyze 
aggregate signal derived from multiple EVs after they are bound to micrometer polystyrene 
capture beads (Koliha, Wiencek et al. 2016). Stimulated emission depletion (STED) 
microscopy can also be used to measure multiple markers on single EVs, but this approach 
does not appear suitable for the analysis of rare EV populations without a prior isolation 
step.  
 Several groups have recently reported robust on-chip isolation and detection methods 
to study and profile EVs. In 2014, a group reported the development of a nanoplasmonic 
EV (nPLEX) sensor consisting of an affinity ligand-modified gold film that contained an 
array of periodic nanoholes, in which EV binding produced a spectral shift proportional to 
the number of targeted EVs bound on the array (Im, Shao et al. 2014). In 2015, a second 
group reported the development of an immunomagnetic EV RNA (iMER) platform for on-
chip EV enrichment, RNA isolation, reverse transcription and real-time analysis of distinct 
RNA targets, which they used for treatment-induced mRNA in glioblastoma multiforme 
patients (Shao, Chung et al. 2015). In 2017, we published a nanoplasmonic enhanced 
scattering (nPES) method where EVs are bound to a chip by a pan-specific EV antibody, 
and hybridized with antibody-labeled nanoparticles specific to a second common EV 
protein and a disease-specific EV marker so that target EVs produce a shifted nPES signal 
in direct proportion to their number (Liang, Liu et al. 2017). All these technologies should 
allow one to modify the EV targets analyzed by changing the affinity of the detection 
antibody or ligand, and thus should be readily adaptable for any disease for which there is 
a disease-specific EV biomarker available. None of these approaches are yet available for 
clinical applications, but they demonstrate the potential of new chip technologies to rapidly 
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profile disease-specific EVs from human samples after minimal sample preparation. 
 Mounting evidence indicates pathogen-derived EV factors play important roles in 
several human diseases, and a better understanding of these mechanisms may provide new 
insights for future therapeutic development. Several reports indicate that 
immunomodulatory molecules present in or on EVs can affect pathogen responses through 
actions to activate or suppress immune responses, and it is possible that increased 
knowledge of these mechanisms will improve pathogen treatment approaches, including 
the potential use of EVs to develop more effective vaccines and immunotherapies. 
Pathogen-specific EV factors are also of great interest as novel disease biomarkers, due to 
their close association with disease and their potential for greater diagnostic sensitivity and 
specificity due to their stability in blood and urine. Specific EV biomarkers and means to 
analyze specific EV subsets have been lacking to date, however  The Qdot assay can be 
easily modified to address different infectious disease conditions by the substitution of 
different EV biomarker probes, and is limited only by the existence of such probes and the 
ability to identify EV capture antibodies specific for an EV population of interest. 
 
7.2.2. Clinical Translation 
There are tremendous ongoing efforts focused on discovering novel cancer 
biomarkers for use in clinical practice. However, one of the issues in translation into the 
clinical setting is the limited knowledge researchers possess of analytical, diagnostic, and 
regulatory requirements for a clinical assay (Pepe, Etzioni et al. 2001, Fuzery, Levin et al. 
2013). As part of our study, we aim to establish a clinically accessible biomarker test that 
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will help improve diagnostic outcomes. Below is a flow chart elaborating on each process 
required to study and validate the biomarker assay development (Figure 39) 
 
 
Figure 39. Schematic overview of the different steps for validation and clinical translation 
of a biomarker assay. 
 
Biomarker assay validation:  
 By achieving sensitive EV detection and quantification without the need for a 
separate pre-purification step. The design will focus on using serum/plasma 
samples that bind to an EV-specific marker (capture antibody).  
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 The next step will focus on designing and validating the quantum dot probes for 
biomarker detection (measuring sensitivity and specificity).  
 Determining the sample/cohort to test such as pancreatic cancer patients for 
different stages, pre-cancer lesion patients, and normal patient samples. Finally, 
determining the limit of detection for the assay with reliable and reproducible 
results. 
Analytical and clinical validation:  
 Determining the robustness of the assay, testing for analytical as well as clinical 
validation (cohort size).  
 Incorporating assay onto a single platform, determining the instruments for readout, 
easy transition from existing laboratory to a diagnostic platform.  
 Designing tests to measure clinical sensitivity and specificity, e.g. distinguishing 
between normal and diseased patients, determining the diagnostic accuracy and 
testing clinical performance on a study group that is representative of the target 
patient population.  
Regulatory approval and clinical implementation: 
 Protein-based biomarker assay used for diagnostics are considered by the FDA to 
be medical devices and follow the same regulatory standards as other types of 
medical devices (Fuzery, Levin et al. 2013).  
 The current available FDA approved pancreatic cancer marker CA19-9 followed 
the 510 (k) FDA pathway. This is for moderate risk, Class II medical devices.  
                                                                                                                      
 
91 
 We would similarly follow the 510 (k) pathway, once the FDA and sponsor (firm 
submitting the pre-market approval application) have agreed on the intended use; 
the biomarker test will then be reviewed under 510(k) guidelines.  
 Finally, accounting for clinical challenges, handling steps for the assay 
interpretation of multiplexed data and workflow acceptance by clinicians. 
 
To be successful, one should develop a plan and take into consideration the key steps that 
are critical in this process, by defining the assay importance both for analytical and clinical 
performances. 
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A MATLAB CODE FOR ROC FOR SINGLE MARKERS AND COMBINED 
MARKERS 
Close all; 
Clear all; 
load ('ROCcombinedvalues053019.mat'); 
%% Individual 
% Marker 1 
range_control = 1:12; 
range_cancer = 1:20; 
range_cancer2 = 13:32; 
 
M1_norm = [ZhaoClinicalMeryl2 {range_control,'Control'} ; 
ZhaoClinicalMeryl2{range_cancer, 'Cancer'}]; 
pred_ind = M1_norm; 
Y = []; Y(range_control,1) = 0; Y(range_cancer2,1) = 1; % Combining control and 
cancer in a single variable and indication with 0 and 1.  
mdl_ind1 = fitglm (pred_ind,Y,'Distribution','binomial','Link','logit'); 
labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores_ind = mdl_ind1.Fitted.Probability; 
[X_ind1,Y_ind1,T_ind1, AUC_ind1] = perfcurve(labels,scores_ind,'Cancer'); 
 
% Un - normalized data 
M1_unnorm = [ZhaoClinicalMeryl2{range_control,'Control2'} ; 
ZhaoClinicalMeryl2{range_cancer, 'Cancer2'}]; 
 
pred_ind2 = M1_unnorm; 
mdl_ind2 = fitglm(pred_ind2,Y,'Distribution','binomial','Link','logit'); 
 
labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores_ind2 = mdl_ind2.Fitted.Probability; 
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[X_ind2,Y_ind2,T_ind2,AUC_ind2] = perfcurve(labels,scores_ind2,'Cancer'); 
 
figure(); 
plot(X_ind1, Y_ind1,'LineWidth',2); hold on; 
plot(X_ind2,Y_ind2, 'LineWidth',2); 
legend('DiO-Normalized EpCAM (AUC:0.95)','Raw EpCAM (AUC: 
0.77)','FontSize',12); 
set(gca,'FontSize',9); 
ylabel('Sensitivity','FontSize',16);  
xlabel('1 - Specificity','FontSize',16); 
% title('ROC Curve Analysis-EpCAM'); 
 
 
% Marker 2 
M2_norm = [ZhaoClinicalMeryl2{range_control,'Control1'} 
;ZhaoClinicalMeryl2{range_cancer, 'Cancer1'}]; 
pred_ind3 = M2_norm; 
Y = []; Y(range_control,1) = 0; Y(range_cancer2,1) = 1; 
mdl_ind3 = fitglm(pred_ind3,Y,'Distribution','binomial','Link','logit'); 
labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores_ind3 = mdl_ind3.Fitted.Probability; 
[X_ind3,Y_ind3,T_ind3, AUC_ind3] = perfcurve(labels,scores_ind3,'Cancer'); 
 
% Un - normalized data 
M2_unnorm = [ZhaoClinicalMeryl2{range_control,'Control3'} 
ZhaoClinicalMeryl2{range_cancer, 'Cancer3'}]; 
 
 
pred_ind4 = M2_unnorm; 
mdl_ind4 = fitglm(pred_ind4,Y,'Distribution','binomial','Link','logit'); 
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labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores_ind4 = mdl_ind4.Fitted.Probability; 
[X_ind4,Y_ind4,T_ind4,AUC_ind4] = perfcurve(labels,scores_ind4,'Cancer'); 
 
figure(); 
plot(X_ind3, Y_ind3, 'LineWidth',2); hold on; 
plot(X_ind4,Y_ind4,'LineWidth',2); 
legend('DiO-Normalized EphA2 (AUC:0.97)','Raw EphA2 (AUC: 0.82)','FontSize',12); 
set(gca,'FontSize',9); 
ylabel('Sensitivity','FontSize',16);  
xlabel('1 - Specificity','Fontsize',16); 
% title('ROC Curve Analysis EphA_2'); 
 
%% Combined Markers 
% Reorganize data 
M1_norm = [ZhaoClinicalMeryl2{range_control,'Control'} ; 
ZhaoClinicalMeryl2{range_cancer, 'Cancer'}]; 
M2_norm = [ZhaoClinicalMeryl2{range_control,'Control1'} 
;ZhaoClinicalMeryl2{range_cancer, 'Cancer1'}]; 
pred = [M1_norm M2_norm]; 
Y = []; Y(range_control,1) = 0; Y(range_cancer2,1) = 1; 
mdl_comb1 = fitglm(pred,Y,'Distribution','binomial','Link','logit'); 
labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores = mdl_comb1.Fitted.Probability; 
[X_norm,Y_norm,T_norm, AUC_norm] = perfcurve(labels,scores,'Cancer'); 
 
% Un - normalized data 
M1_unnorm = [ZhaoClinicalMeryl2{range_control,'Control2'} ; 
ZhaoClinicalMeryl2{range_cancer, 'Cancer2'}]; 
                                                                                                                      
 
113 
M2_unnorm = [ZhaoClinicalMeryl2{range_control,'Control3'} ; 
ZhaoClinicalMeryl2{range_cancer, 'Cancer3'}]; 
pred2 = [M1_unnorm M2_unnorm]; 
mdl_comb2 = fitglm(pred2,Y,'Distribution','binomial','Link','logit'); 
labels = strings ; labels(range_control,1) = 'Control'; labels(range_cancer2,1) = 'Cancer'; 
scores_2 = mdl_comb2.Fitted.Probability; 
[X_unnorm,Y_unnorm,T_unnorm,AUC_unnorm] = perfcurve(labels,scores_2,'Cancer'); 
 
figure(); 
plot(X_norm, Y_norm, 'LineWidth',2,'Color','k'); hold on; 
plot(X_unnorm,Y_unnorm,'LineWidth',2,'Color','g'); 
legend('DiO-Normalized EpCAM EphA2 (AUC:0.95)','Raw EpCAM EphA2 (AUC: 
0.77)','FontSize',12); 
set(gca,'FontSize',9); 
ylabel('Sensitivity','FontSize',16);  
xlabel('1 - Specificity','FontSize',16); 
% title('ROC Curve Analysis - Combined'); 
 
